<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533611431068</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533611431068</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Supplementation of Essential Amino Acids May Reduce the Occurrence of Infections in Rehabilitation Patients With Brain Injury</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Boselli</surname><given-names>Mirella</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533611431068">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Aquilani</surname><given-names>Roberto</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0884533611431068">2</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Baiardi</surname><given-names>Paola</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-0884533611431068">3</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Dioguardi</surname><given-names>Francesco Saverio</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0884533611431068">4</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Guarnaschelli</surname><given-names>Caterina</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533611431068">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Achilli</surname><given-names>Maria Pia</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533611431068">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Arrigoni</surname><given-names>Nadia</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533611431068">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Iadarola</surname><given-names>Paolo</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff5-0884533611431068">5</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Verri</surname><given-names>Manuela</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff6-0884533611431068">6</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Viglio</surname><given-names>Simona</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff5-0884533611431068">5</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Barbieri</surname><given-names>Annalisa</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff7-0884533611431068">7</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western"><surname>Boschi</surname><given-names>Federica</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff7-0884533611431068">7</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533611431068"><label>1</label>Unità di Riabilitazione Neuromotoria, Unità Gravi Cerebrolesioni Acquisite, Fondazione S. Maugeri, IRCCS, Istituto Scientifico di Montescano, Montescano, Pavia, Italy</aff>
<aff id="aff2-0884533611431068"><label>2</label>Servizio di Fisiopatologia Metabolico-Nutrizionale e Nutrizione Clinica, Fondazione S. Maugeri, IRCCS, Istituto Scientifico di Montescano, Montescano, Pavia, Italy</aff>
<aff id="aff3-0884533611431068"><label>3</label>Consorzio Valutazioni Biologiche e Farmacologiche, Fondazione S. Maugeri e Università degli Studi di Pavia, Pavia, Italy</aff>
<aff id="aff4-0884533611431068"><label>4</label>Dipartimento di Medicina Interna, Università di Milano, Milano, Italy</aff>
<aff id="aff5-0884533611431068"><label>5</label>Dipartimento di Biochimica “A. Castellani,” Università degli Studi di Pavia, Pavia, Italy</aff>
<aff id="aff6-0884533611431068"><label>6</label>Dipartimento di Medicina Legale, Scienze Forensi e Farmaco-Tossicologiche “A. Fornari,” Sezione di Scienze Farmacologiche e Tossicologiche, Università degli Studi di Pavia, Pavia, Italy</aff>
<aff id="aff7-0884533611431068"><label>7</label>Dipartimento di Scienze del Farmaco, Università degli Studi di Pavia, Pavia, Italy</aff>
<author-notes>
<corresp id="corresp1-0884533611431068">Federica Boschi, Dipartimento di Scienze del Farmaco, Università degli Studi di Pavia-Viale Taramelli, 12-27100 Pavia, Italy; e-mail: <email xlink:type="simple">federica.boschi@unipv.it</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>1</issue>
  <issue-title>Micronutrients</issue-title>
<fpage>99</fpage>
<lpage>113</lpage>
<history>
<date date-type="received">
<day>2</day>
<month>5</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: To investigate whether supplementation with oral essential amino acids (EAAs) may reduce the occurrence of nosocomial infection among patients with brain injury (BI: stroke, trauma, anoxic coma). <italic>Methods</italic>: Patients (n = 125; 77 men, 48 women; mean age 63 ± 15 years) with stroke (68.8%), subarachnoid hemorrhage (17.6%), traumatic BI (7.2%), and anoxic BI (6.4%) 88 ± 15days after the index event. Patients were randomly assigned to 2 months of oral EAAs (n = 63; 8 g/d) or placebo (n = 62). <italic>Results</italic>: Over the first month of rehabilitation, there were 60 infections in the whole population of 125 patients (48%); however, the rate was 23.2% lower in the EAA group (23 episodes/63 patients; 36.5%) than in the placebo group (37 episodes/62 patients; 59.7%) (<italic>P</italic> &lt; .01). The types of infection were similarly distributed between the 2 groups. Serum levels of prealbumin &lt;20 mg/dL and C-reactive protein (CRP) &gt;0.3 mg/dL were the best predictors of future infection (prealbumin: odds ratio [OR] = 4.17, confidence interval [CI] 1.84–9.45, <italic>P</italic> &lt; .001; CRP: OR = 3.8, CI 1.71-8.44, <italic>P</italic> &lt; .001). <italic>Conclusion</italic>: Supplementary EAAs may reduce the occurrence of nosocomial infections in rehabilitation patients with BI. Prealbumin and CRP are the best predictors of future infections.</p>
</abstract>
<kwd-group>
<kwd>amino acids, essential</kwd>
<kwd>infection</kwd>
<kwd>brain injuries</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Infection often complicates the rehabilitation period of patients with brain injury (BI), whether the cause is ischemic/hemorrhagic stroke (ST), subarachnoid hemorrhage (SH), or anoxic traumatic insult (A/T). Infection affects functional outcomes, increases length of stay,<sup><xref ref-type="bibr" rid="bibr1-0884533611431068">1</xref></sup> and negatively influences both patients’ life and functional prognosis.<sup><xref ref-type="bibr" rid="bibr2-0884533611431068">2</xref></sup></p>
<p>The incidence rate of infection during rehabilitation has been reported to range from 16.5%<sup><xref ref-type="bibr" rid="bibr3-0884533611431068">3</xref></sup>−34.5%<sup><xref ref-type="bibr" rid="bibr4-0884533611431068">4</xref></sup> in patients with ST and to be 45% in post-A/T<sup><xref ref-type="bibr" rid="bibr5-0884533611431068">5</xref></sup>; infection in patients with SH undergoing rehabilitation has not been documented, whereas the infection rate is 46% in patients with acute SH.<sup><xref ref-type="bibr" rid="bibr2-0884533611431068">2</xref></sup></p>
<p>In our tertiary care rehabilitation institute for patients with BI, the rate of development or exacerbation of infection within the first month after admission is about 60% (unpublished data). This high infection rate reflects the severity of the patients’ clinical and functional compromise<sup><xref ref-type="bibr" rid="bibr6-0884533611431068">6</xref></sup> following their primary disease but also suggests a relative inadequacy of the measures adopted to prevent infections.<sup><xref ref-type="bibr" rid="bibr7-0884533611431068">7</xref>-<xref ref-type="bibr" rid="bibr9-0884533611431068">9</xref></sup></p>
<p>Rehabilitation patients with BI are particularly prone to the development or exacerbation of infection because of their immunodeficiency state.<sup><xref ref-type="bibr" rid="bibr10-0884533611431068">10</xref>-<xref ref-type="bibr" rid="bibr12-0884533611431068">12</xref></sup> Central nervous system injury induces a disturbance of homeostatic mechanisms between the immune system and the brain, responsible for immunodeficiency and infectious complications.<sup><xref ref-type="bibr" rid="bibr10-0884533611431068">10</xref></sup> The processes contributing to this immunity-brain disturbance include post–acute injury systemic inflammatory response syndrome (SIRS)<sup><xref ref-type="bibr" rid="bibr13-0884533611431068">13</xref>-<xref ref-type="bibr" rid="bibr15-0884533611431068">15</xref></sup> and counterinflammatory response syndrome (CIRS),<sup><xref ref-type="bibr" rid="bibr16-0884533611431068">16</xref></sup> which both play major roles. Additive factors may contribute to further impair patients’ immunological defences. These include abnormal mental status, coma, aspiration,<sup><xref ref-type="bibr" rid="bibr2-0884533611431068">2</xref></sup> the provenience of patients (neurological and neurosurgical intensive care units),<sup><xref ref-type="bibr" rid="bibr2-0884533611431068">2</xref></sup> blood transfusion,<sup><xref ref-type="bibr" rid="bibr17-0884533611431068">17</xref></sup> length of stay in the hospital,<sup><xref ref-type="bibr" rid="bibr18-0884533611431068">18</xref></sup> metabolic stress response,<sup><xref ref-type="bibr" rid="bibr19-0884533611431068">19</xref></sup> a hypermetabolic state in the acute stage of BI,<sup><xref ref-type="bibr" rid="bibr20-0884533611431068">20</xref></sup> poor nutrition,<sup><xref ref-type="bibr" rid="bibr21-0884533611431068">21</xref></sup> possible multiple trauma (in traumatic BI),<sup><xref ref-type="bibr" rid="bibr22-0884533611431068">22</xref></sup> and use of concomitant medical devices.<sup><xref ref-type="bibr" rid="bibr2-0884533611431068">2</xref></sup></p>
<p>The implementation of preventive measures aimed at reducing the infection rate of rehabilitation patients with BI is, therefore, of clinical importance and can reduce the financial burden for hospitals. The central hypothesis of the present study is that, in addition to preventive measures, enhancing/improving patients’ defense capacities could play a critical role in limiting the occurrence of infection in rehabilitation patients with BI and that this reinforcement of patients’ immune responses could be achieved by supplementation of essential amino acids (EAAs).</p>
<p>This hypothesis is based on four main considerations. First, EAAs are the building block of every process of protein synthesis<sup><xref ref-type="bibr" rid="bibr23-0884533611431068">23</xref></sup>: the shortage of even only 1 EAA can reduce the rate of protein synthesis. Second, protein synthesis is necessary and increased during the post–acute period following BI characterized by systemic and intracranial inflammatory responses.<sup><xref ref-type="bibr" rid="bibr24-0884533611431068">24</xref>,<xref ref-type="bibr" rid="bibr25-0884533611431068">25</xref></sup> Third, protein synthesis is necessary for the high rate of proliferation, duplication,<sup><xref ref-type="bibr" rid="bibr26-0884533611431068">26</xref></sup> and phagocytosis<sup><xref ref-type="bibr" rid="bibr27-0884533611431068">27</xref>,<xref ref-type="bibr" rid="bibr28-0884533611431068">28</xref></sup> of immune cells. Last, the efficacy of EAAs has been documented in octogenarian patients undergoing intensive rehabilitation for diseases other than BI,<sup><xref ref-type="bibr" rid="bibr7-0884533611431068">7</xref></sup> among whom the occurrence of infection was reduced by 30%.</p>
<p>In the present study, therefore, we investigated the effect of EAA supplementation on the rate of infections among rehabilitation patients with BI. In addition, we identified possible risk factors for developing infection.</p>
<sec id="section1-0884533611431068" sec-type="methods">
<title>Methods</title>
<sec id="section2-0884533611431068">
<title>Clinical Setting</title>
<p>The policy of our clinical rehab division is to admit all BI patients independently of the time the acute event arises, as soon as their functional status worsens and/or neurocognitive level deteriorates despite a rehab program carried out in other hospitals.</p>
<p>Clinical interventions also aim to highlight clinical and neurological factors that cause patient worsening and to indicate secondary prevention measures for infection at the time of patient discharge from the rehab setting.</p>
</sec>
<sec id="section3-0884533611431068">
<title>Population</title>
<p>One hundred seventy-five patients with BI (88.3 ± 110 days after acute event; range, 5-447; median 43) were consecutively admitted to our rehab division from October 1, 2009, to September 30, 2010, and were enrolled in this randomized, double-blind, placebo-controlled study. Criteria for exclusion were the presence or occurrence of intracerebral hypertension, hydrocephalus, complications from neurosurgery, admission antibiotic therapy, pressure ulcer with infection clinically evaluated by the presence of purulent fluid, presence of fever with a temperature &gt;36.8°C, chronic heart failure, acute coronary artery disease, acute and chronic renal failure (creatinine clearance &lt;30 mg/100 mL), cancer, or surgery for cancer.</p>
<p>We adopted these selection criteria to avoid existing infection and diseases that, per se, represent a very high risk for infection and/or are life threatening. The patients had been admitted from general intensive care units (ICUs; 16%), neurosurgery ICUs (14.8%), stroke units (31.4%), a neurological setting (18.4%), and the home (because of worsening of neurological symptoms) (19.4%).</p>
<p>The study was approved by the ethical, technical-scientific committee of our institute. Written informed consent was obtained from participants after the nature of the study had been explained. For those patients with cognitive dysfunction, informed consent was obtained from the patients’ caregivers, who were carefully informed that EAAs should not be considered drugs but rather as nutrition substrates with the potential of acting on immunological defenses.</p>
</sec>
<sec id="section4-0884533611431068">
<title>Procedure</title>
<p>Within the first week after admission and at discharge, the following assessments were made:</p>
<list id="list1-0884533611431068" list-type="alpha-lower">
<list-item><p>Anthropometric characteristics: body weight (kg), determined using a mechanical weight lifter; height (m), calculated from knee height<sup><xref ref-type="bibr" rid="bibr29-0884533611431068">29</xref></sup>; and body mass index (BMI), calculated as kg/m<sup>2</sup></p></list-item>
<list-item><p>Biohumoral variables: after overnight fasting, at 8:00 <sc>am</sc>, blood samples from an arm peripheral vein were drawn to determine the following:</p>
<list id="list2-0884533611431068" list-type="order">
<list-item><p>Routine variables</p></list-item>
<list-item><p>Biomarkers of body inflammatory status including serum levels of: interleukin-6 (IL-6), determined in duplicate using a high-sensitivity commercial sandwich enzyme-linked immunosorbent assay (ELISA) kit from Mabtech (Agilent Technologies GmbH, Boblingen, Germany); C-reactive protein (CRP), determined by an immunoturbidimetric method; acute phase reactant proteins (fibrinogen, haptoglobin); and nonreactant proteins (albumin, prealbumin, and transferrin) were also measured.</p></list-item>
<list-item><p>Plasma EAAs: leucine, valine, isoleucine, methionine, phenylalanine, tryptophan, lysine, and threonine. The concentration of free amino acids in plasma was measured by an AminoQuant II (Milan, Italy) amino acid analyzer, based on the HP 1090 HPLC system, with fully automated precolumn derivatization, by using both ortho-phthalaldehyde and 9-fluorenyl-methyl-chloroformate reaction chemistries according to the manufacturer’s protocol. Determinations were performed essentially by injecting 1 µL of the derivatized mixture and measuring absorbance simultaneously at 338 and 262 nm. Plasma concentrations were expressed as µmol/L. In our laboratory, a normal value of the sum of the EAAs is 862 ± 122 µmol/L (range, 710–1066 µmol/L) and 32.3% ± 4.5% of total amino acids (range, 27.6%–39.7%). Although we have determined all the amino acids (nonessential and essential amino acids) both at admission and discharge times, we discussed only the EAA at admission of patients to our institute.</p></list-item>
</list>
</list-item>
<list-item><p>Functional status: the functional status of patients was evaluated by means of a functional independence measure (FIM)<sup><xref ref-type="bibr" rid="bibr30-0884533611431068">30</xref></sup> or disability rating scale (DRS) when appropriate.<sup><xref ref-type="bibr" rid="bibr31-0884533611431068">31</xref></sup></p></list-item>
<list-item><p>Nutrition intakes: for self-feeding patients (85%), a 3-day alimentary diary was kept by rehabilitation nurses who had been previously trained ad hoc. The nurses recorded the type and weight of cooked or uncooked food selected by patients from the hospital menu on a diet sheet for 3 days before and after the patients’ meals. The amount of food really ingested was converted (by R.A.) to the raw equivalent, when necessary, using appropriate tables.<sup><xref ref-type="bibr" rid="bibr32-0884533611431068">32</xref></sup> Nutrition analysis, carried out using a computer program designed by our group,<sup><xref ref-type="bibr" rid="bibr33-0884533611431068">33</xref></sup> was used to calculate actual ingested calories, macro-/micronutrients, and amino acids. In our laboratory, dietary ingestion of EAAs is 25%–35% of total ingested amino acids.</p></list-item>
</list>
</sec>
<sec id="section5-0884533611431068">
<title>Randomization of Patients</title>
<p>After completing all these procedures, the patients were assigned to treatment according to a randomized allocation procedure. A randomization list was generated using SAS statistical software (SAS Institute, Cary, NC). A and B were the identifiers of the blinded treatment. The list was made available both to physicians (M.B., MP.A., N.A.) and to the hospital pharmacists. The physicians sequentially allocated patients to treatment A or B according to a randomization list. The second author (R.A.) who interpreted all results was blinded to the patients’ allocation. The experimental group (EAA group) received an oral (or via feeding tube in tube-fed patients) nutrition mixture supplement that provided 8 g of EAAs/d (Aminotrophic, Professional Dietetics, Milan, Italy; <xref ref-type="table" rid="table1-0884533611431068">Table 1</xref>; 4 g in the morning + 4 g in the afternoon diluted in half a glass of water) for 60 days. The placebo group (control group) was given a similar isocaloric product containing maltodextrin instead of EAAs. Rehabilitation nurses assisted every patient during the intake of placebo or EAAs to be certain about the patients’ compliance.</p>
<table-wrap id="table1-0884533611431068" position="float">
<label>Table 1.</label>
<caption><p>Nutrition Composition of an Individual Packet of Supplementation, Containing 4 g of an Amino Acid Mixture, Used in This Study<sup><xref ref-type="table-fn" rid="table-fn1-0884533611431068">a</xref></sup></p></caption>
<graphic alt-version="no" alternate-form-of="table1-0884533611431068" position="float" xlink:href="10.1177_0884533611431068-table1.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<tbody>
<tr>
<td colspan="1" rowspan="1">kcal</td>
<td colspan="1" rowspan="1">20.6</td>
</tr>
<tr>
<td colspan="1" rowspan="1">KJ</td>
<td colspan="1" rowspan="1">86.1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total amino acids, including the following:</td>
<td colspan="1" rowspan="1">4 g</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-leucine</td>
<td colspan="1" rowspan="1">1250 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-lysine</td>
<td colspan="1" rowspan="1">650 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-isoleucine</td>
<td colspan="1" rowspan="1">625 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-valine</td>
<td colspan="1" rowspan="1">625 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-threonine</td>
<td colspan="1" rowspan="1">350 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-cysteine</td>
<td colspan="1" rowspan="1">150 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-histidine</td>
<td colspan="1" rowspan="1">150 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-phenylalanine</td>
<td colspan="1" rowspan="1">100 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-methionine</td>
<td colspan="1" rowspan="1">50 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-tyrosine</td>
<td colspan="1" rowspan="1">30 mg</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> L-tryptophan</td>
<td colspan="1" rowspan="1">20 mg</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533611431068">
<label>a</label>
<p>Treated patients were given 2 packets daily (8 g essential amino acids).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The nurses were blinded to the type of supplementation (maltodextrin or EAAs) given the patients because the packets containing the products were identical but numbered as 1 or 2. The contents were known only to the physicians (M.B., MP.A., N.A.) and the pharmacists (1 = placebo; 2 = EAAs). The product content in the packets 1 and 2 had similar color and taste.</p>
<p>For patients receiving enteral nutrition (EN), the aqueous solution of EAAs was supplied through the feeding tube (nasogastric or percutaneous endoscopy gastrostomy).</p>
<p>The duration of the study was 60 days from the randomization procedure. After randomization, patients were surveyed daily by rehabilitation nurses for evidence of infection. A diagnosis of infection was made by a physician on the basis of described criteria for initiating antibiotics.</p>
</sec>
<sec id="section6-0884533611431068">
<title>Criteria for Diagnosing Infection<sup><xref ref-type="bibr" rid="bibr2-0884533611431068">2</xref></sup></title>
<list id="list3-0884533611431068" list-type="simple">
<list-item><p><italic>Pneumonia</italic>: diagnosed according to American College of Chest Physicians criteria in patients who had a new infiltrate on chest x-ray plus 1 of the 3 following conditions: elevated white blood cell count (more then 10,000 cells/mL), fever, or purulent sputum<sup><xref ref-type="bibr" rid="bibr34-0884533611431068">34</xref></sup></p></list-item>
<list-item><p><italic>Urinary tract infection</italic>: was defined as pyuria with more than 5 white blood cells/hpf with a positive urine culture with more than 100,000 colonies<sup><xref ref-type="bibr" rid="bibr35-0884533611431068">35</xref></sup></p></list-item>
<list-item><p><italic>Bloodstream infection</italic>:</p>
<list id="list4-0884533611431068" list-type="alpha-lower">
<list-item><p>Microbiologically documented: recognized pathogen in the blood not related to an infection at another site or fever (&gt;37.5°C), chills, or hypotension and any of the following: common skin contaminant isolated from (1) at least 2 positive blood cultures drawn on separate occasions or (2) a positive blood culture in a patient with an intravascular device. The organism is not related to infection at another site.</p></list-item>
<list-item><p>Clinically diagnosed: when the patient had fever, hypotension, or oliguria plus (1) no microorganism cultured or isolated from the blood, (2) no infection at another site, or (3) physician instituted appropriate antimicrobial therapy for sepsis<sup><xref ref-type="bibr" rid="bibr36-0884533611431068">36</xref></sup></p></list-item>
</list>
</list-item>
<list-item><p><italic>Gastroenteritis</italic>: one of the following criteria had to be met:</p>
<list id="list5-0884533611431068" list-type="alpha-lower">
<list-item><p>2 or more loose or watery stools over a day</p></list-item>
<list-item><p>2 or more episodes of vomiting in a 24-hour period</p></list-item>
<list-item><p>both of the following: (1) stool culture positive for a pathogen, including <italic>Clostridium difficile</italic> (toxin) and (2) at least 1 symptom compatible with a gastrointestinal tract infection (nausea, vomiting, abdominal pain, or diarrhea)</p></list-item>
</list>
</list-item>
</list>
</sec>
<sec id="section7-0884533611431068">
<title>Statistical Analysis</title>
<sec id="section8-0884533611431068">
<title>Sample size</title>
<p>Assuming type I and type II errors of 0.05 and 0.20, respectively (α = 0.05, β = 0.80) and a 1-sided test, the number of patients required to prove a 20% reduction in the occurrence of infections between the group receiving placebo and that receiving supplementation with EAAs was 62 patients per group. Taking into account a dropout rate of 10%, at least 136 patients had to be enrolled overall.</p>
</sec>
<sec id="section9-0884533611431068">
<title>Data analysis</title>
<p>Descriptive statistics were performed for all recorded variables. The mean and standard deviation were reported for continuous variables; qualitative variables were summarized as frequencies and percentages. The occurrence of infections between the EAA and placebo groups was compared using Pearson’s χ<sup>2</sup> test. Baseline characteristics between EAA and placebo groups were compared using an unpaired Student <italic>t</italic> test or χ<sup>2</sup> test, as appropriate. Trends over time from baseline to discharge were compared between the 2 groups by means of an analysis of variance model with 1 factor. Single and multiple correlation analyses were performed to test the association between FIM/DRS levels at admission and discharge and serum albumin, prealbumin, transferrin, and CRP concentrations. A stepwise procedure was applied to select independent variables highly correlated with FIM/DRS.</p>
<p>Conditional logistic regression analysis was used to test the association between the occurrence of infection and hypothetical risk factors recorded at baseline. Risk factors were initially included as continuous variables in univariate models: variables that were statistically associated with the outcome were dichotomized to identify a risk and reference category and included in a multivariate model. A stepwise procedure was applied to identify the risk factors with the highest predictivity for developing infections. Results were expressed in terms of unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs).</p>
</sec>
</sec>
</sec>
<sec id="section10-0884533611431068" sec-type="results">
<title>Results</title>
<p>From a total of 175 screened patients with BI, 136 met the inclusion criteria and were included in the study (<xref ref-type="fig" rid="fig1-0884533611431068">Figure 1</xref>). Fifteen patients were not included because of complications from neurosurgery or hydrocephalus or intracerebral hypertension, 6 because of advanced chronic renal failure (creatinine clearance &lt;30 mg/dL), 1 because of acute renal failure, 4 because of chronic heart failure, and 13 because they were on antibiotic therapy at the time of admission to the rehabilitation unit.</p>
<fig id="fig1-0884533611431068" position="float">
<label>Figure 1.</label>
<caption><p>Flow diagram indicating the number of patients recruited and registered.</p></caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_0884533611431068-fig1.tif" xlink:type="simple"/>
</fig>
<p>Of 136 patients, 125 completed the study protocol: 11 patients (5 in the treated group and 6 in the placebo group) discontinued the study. The reasons for discontinuation were self-discharge (n = 5), need for surgical intervention (n = 2), myocardial infarct (n = 2), hemorrhagic gastric ulcer (n = 1), and brain hemorrhage recurrence (n = 1). Thus, 63 patients on EAAs and 62 patients on placebo completed the 60-day protocol and were analyzed.</p>
<p>Time from injury event was 85 ± 15 days for placebo patients and 98 ± 25 for EAA patients. From medical referral, 46% of patients allocated in treatment group and 40.3% of the placebo group had suffered from infections after index events over the period prior to their admission to our rehabilitation institute.</p>
<p>Of 125 patients analyzed, 31 (25%) with type II diabetes mellitus and taking insulin or oral hypoglycemic drugs were similarly distributed between the groups (14 in the EAA group, 17 on placebo). Ten (8%; 4 in the placebo group and 6 in treated group) had moderate renal impairment (creatinine clearance 30–59 mL/min).</p>
<sec id="section11-0884533611431068">
<title>Baseline Characteristics</title>
<p>After randomization, the 2 groups of patients were similar in demographics, anthropometric characteristics, types of primary brain insult, medical advice, and nutrition intakes (by spontaneous diet or tube-feeding nutrition; <xref ref-type="table" rid="table2-0884533611431068">Table 2</xref>).</p>
<table-wrap id="table2-0884533611431068" position="float">
<label>Table 2.</label>
<caption><p>Demographic, Clinical, Biohumoral, Anthropometric, and Nutrition Variables and Medical Devices in 2 Groups of Patients After Randomization to Placebo or Supplementation With Essential Amino Acids (EAAs)</p></caption>
<graphic alt-version="no" alternate-form-of="table2-0884533611431068" position="float" xlink:href="10.1177_0884533611431068-table2.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="center" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Variables</th>
<th align="center" colspan="1" rowspan="1">Normal Values</th>
<th align="center" colspan="1" rowspan="1">Placebo Group (n = 62)</th>
<th align="center" colspan="1" rowspan="1">%RDA</th>
<th align="center" colspan="1" rowspan="1">EAA-Supplemented Group (n = 63)</th>
<th align="center" colspan="1" rowspan="1">%RDA</th>
<th align="center" colspan="1" rowspan="1"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7" rowspan="1"><bold>Demographic</bold></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Male/female</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">37/25</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">40/23</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Age, y</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">63.9 ± 17</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">62.7 ± 12.4</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"><bold>Clinical</bold></td>
</tr>
<tr>
<td colspan="7" rowspan="1">Etiology</td>
</tr>
<tr>
<td colspan="7" rowspan="1"> Stroke</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Ischemic (n = 86; 68.8%)</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">45</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">41</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Hemorrhagic (n = 22; 17.6%)</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">13</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Traumatic brain injury (n = 9; 7.2%)</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">5</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">4</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Cardiac arrest/anoxic coma (n = 8; 6.4%)</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">5</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"><bold>Anthropometric</bold></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Body weight, kg</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">72.29 ± 15.26</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">71.63 ± 15.61</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Body mass index, kg/m<sup>2</sup></td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">25.86 ± 4.6</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">25.38 ± 4.55</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"><bold>Blood</bold></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Hemoglobin, g/dL</td>
<td colspan="1" rowspan="1">F &gt;12 M &gt;13</td>
<td colspan="1" rowspan="1">12.94 ± 1.9</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">13.09 ± 1.2</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Urea, mg/dL</td>
<td colspan="1" rowspan="1">20–40</td>
<td colspan="1" rowspan="1">39.8 ± 21.8</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">40.9 ± 20.1</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Creatinine, mg/dL</td>
<td colspan="1" rowspan="1">0.7–1.2</td>
<td colspan="1" rowspan="1">0.96 ± 0.3</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">0.99 ± 0.26</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Glucose, mg/dL</td>
<td colspan="1" rowspan="1">80–110</td>
<td colspan="1" rowspan="1">101.77 ± 26.1</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">118.26 ± 43.2</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">&lt;.01</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Total white cells, n/mm<sup>3</sup></td>
<td colspan="1" rowspan="1">4000–9000</td>
<td colspan="1" rowspan="1">6479 ± 1923</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">6856 ± 1984</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Lymphocytes, %</td>
<td colspan="1" rowspan="1">20–40</td>
<td colspan="1" rowspan="1">27.3 ± 8.83</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">27.8 ± ±10.3</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Albumin, g/dL</td>
<td colspan="1" rowspan="1">3.5–4.8</td>
<td colspan="1" rowspan="1">3.41 ± 0.54</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">3.26 ± 0.56</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Prealbumin, mg/dL</td>
<td colspan="1" rowspan="1">18–30</td>
<td colspan="1" rowspan="1">22.04 ± 5.9</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">19.94 ± 5.39</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">&lt;.05</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Fibrinogen, mg/dL</td>
<td colspan="1" rowspan="1">230–500</td>
<td colspan="1" rowspan="1">401.3 ± 101.4</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">377 ± 91.93</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> C-reactive protein, mg/dL</td>
<td colspan="1" rowspan="1">&lt;0.3</td>
<td colspan="1" rowspan="1">1.48 ± 3.03</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">1.27 ± 1.67</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Daily nutrition intake<sup><xref ref-type="table-fn" rid="table-fn3-0884533611431068">a</xref></sup></td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"> Energy</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  kcal</td>
<td colspan="1" rowspan="1">≥25</td>
<td colspan="1" rowspan="1">1960 ± 340</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">1835 ± 278</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  kcal/kg</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">26.2 ± 4.5</td>
<td colspan="1" rowspan="1">105</td>
<td colspan="1" rowspan="1">24.3 ± 3.66</td>
<td colspan="1" rowspan="1">97.2</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"> Proteins</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  g</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">78.4 ± 8.5</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">73.7 ± 9.1</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  g/kg</td>
<td colspan="1" rowspan="1">≥1.1</td>
<td colspan="1" rowspan="1">1.08 ± 0.23</td>
<td colspan="1" rowspan="1">98</td>
<td colspan="1" rowspan="1">1.03 ± 0.22</td>
<td colspan="1" rowspan="1">94</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"> Lipids</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  g</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">66.6 ± 7.1</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">64.3 ± 5.9</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  g/kg</td>
<td colspan="1" rowspan="1">≤1</td>
<td colspan="1" rowspan="1">0.92 ± 0.19</td>
<td colspan="1" rowspan="1">92</td>
<td colspan="1" rowspan="1">0.89 ± 0.19</td>
<td colspan="1" rowspan="1">89</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"> Carbohydrates</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  g</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">266 ± 61</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">256 ± 54</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  g/kg</td>
<td colspan="1" rowspan="1">2.5–4</td>
<td colspan="1" rowspan="1">3.7 ± 0.77</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">3.57 ± 0.77</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Calcium, mg</td>
<td colspan="1" rowspan="1">1000</td>
<td colspan="1" rowspan="1">1333 ± 225</td>
<td colspan="1" rowspan="1">133</td>
<td colspan="1" rowspan="1">1285 ± 194</td>
<td colspan="1" rowspan="1">128</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Phosphorus, mg</td>
<td colspan="1" rowspan="1">1000</td>
<td colspan="1" rowspan="1">1333 ± 204</td>
<td colspan="1" rowspan="1">133</td>
<td colspan="1" rowspan="1">1285 ± 175</td>
<td colspan="1" rowspan="1">128</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Potassium, mg</td>
<td colspan="1" rowspan="1">3100</td>
<td colspan="1" rowspan="1">2900 ± 650</td>
<td colspan="1" rowspan="1">93</td>
<td colspan="1" rowspan="1">2796 ± 592</td>
<td colspan="1" rowspan="1">90</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Sodium, mg</td>
<td colspan="1" rowspan="1">ND</td>
<td colspan="1" rowspan="1">1725 ± 152</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">1663 ± 103</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Iron, mg</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">12 ± 2.5</td>
<td colspan="1" rowspan="1">120</td>
<td colspan="1" rowspan="1">11 ± 1.5</td>
<td colspan="1" rowspan="1">110</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Zinc, mg</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">9.8 ± 1.9</td>
<td colspan="1" rowspan="1">98</td>
<td colspan="1" rowspan="1">7.6 ± 0.8</td>
<td colspan="1" rowspan="1">76</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Copper, mg</td>
<td colspan="1" rowspan="1">1.2</td>
<td colspan="1" rowspan="1">1.1 ± 0.3</td>
<td colspan="1" rowspan="1">92</td>
<td colspan="1" rowspan="1">0.9 ± 0.3</td>
<td colspan="1" rowspan="1">75</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Iodide, mcg</td>
<td colspan="1" rowspan="1">ND</td>
<td colspan="1" rowspan="1">108 ± 14.5</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">104 ± 20.5</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="7" rowspan="1"><bold>Devices</bold></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Endotracheal tube</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">4/4</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">4/4</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Bladder catheter</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">19/41</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">22/41</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Venous catheter</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Central</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">7/15</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">8/15</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Peripheral</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">19/32</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">13/32</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Tube feeding</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">8/19</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">11/19</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0884533611431068">
<p>Data are expressed as mean ± SD unless indicated otherwise. Statistical analysis: unpaired <italic>t</italic> test and χ<sup>2</sup> test when appropriate. Placebo group vs essential amino acid–supplemented group. RDA, recommended daily allowance; ND, not defined; <italic>NS</italic>, not significant.</p>
</fn>
<fn id="table-fn3-0884533611431068">
<label>a</label>
<p>The values represent the average of combined spontaneous diet and tube-feeding nutrition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Among nutrition intakes, the ingestion of EEAs in the diet was within the range of normal values of our laboratory (25%–35%) and similar between the 2 groups, being 27.1 ± 3.5 g/d (34.45% ± 6% total ingested amino acids) in placebo patients and 27.78 ± 4.1 g/d (39% ± 5.8% of total ingested amino acids) in the EAA group (<italic>NS</italic>). However, when supplemental EAA in the experimental group was considered (8 g/d), the total intake of EAA in the experimental group was 35.78 g/d or 43.8% ± 6% of total ingested amino acids (<italic>P</italic> &lt; .02 vs placebo).</p>
<p>With respect to biohumoral variables, there were no significant intergroup differences except for blood glucose and serum prealbumin levels, which were, respectively, higher (<italic>P</italic> &lt; .01) and lower (<italic>P</italic> &lt; .05) in treated patients and patients on placebo.</p>
<p>The 2 groups were similar for plasma content in EAAs: 901 ± 181 µmol/L in the placebo group and 983 ± 193 µmol/L in the EAA group.</p>
<p>The degree of disability evaluated by FIM or DRS was similar between treated and nontreated patients.</p>
</sec>
<sec id="section12-0884533611431068">
<title>EAAs and Occurrence of Infections</title>
<p>The study showed that when considering all patients as an entire group, 60 of 125 (48%) had single infection events over the first month. It should be emphasized that each patient developed a single infection event over the first month. Over the total period of rehabilitation (2 months), the infection rate was 77 of 125 (61.6%).</p>
<p>When the 2 groups were analyzed separately, the incidence of infections in the first month of rehabilitation was 23.2% lower in the EAA group (23/63 patients; 36.5%) than in the placebo group (37/62 patients; 59.7%) (<italic>P</italic> &lt; .01). The types of infection were similarly distributed between treated and placebo subgroups (<xref ref-type="table" rid="table3-0884533611431068">Table 3</xref>).</p>
<table-wrap id="table3-0884533611431068" position="float">
<label>Table 3.</label>
<caption><p>Number of Single Infections Developed in the Placebo and Treated Groups Over the First Month of Rehabilitation</p></caption>
<graphic alt-version="no" alternate-form-of="table3-0884533611431068" position="float" xlink:href="10.1177_0884533611431068-table3.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="center" span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1"/>
<th align="center" colspan="1" rowspan="1">Total, No. (%)</th>
<th align="center" colspan="1" rowspan="1">Placebo Group</th>
<th align="center" colspan="1" rowspan="1">EAA-Treated Group</th>
<th align="center" colspan="1" rowspan="1"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">No. of infections</td>
<td colspan="1" rowspan="1">60</td>
<td colspan="1" rowspan="1">37</td>
<td colspan="1" rowspan="1">23</td>
<td colspan="1" rowspan="1">&lt;.01</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Distribution</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Urinary tract</td>
<td colspan="1" rowspan="1">44 (73.3)</td>
<td colspan="1" rowspan="1">26</td>
<td colspan="1" rowspan="1">18</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Respiratory tract</td>
<td colspan="1" rowspan="1">8 (13.3)</td>
<td colspan="1" rowspan="1">5</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Skin</td>
<td colspan="1" rowspan="1">2 (3.3)</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Gastrointestinal Tract</td>
<td colspan="1" rowspan="1">2 (3.3)</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">0</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Blood</td>
<td colspan="1" rowspan="1">4 (6.7)</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0884533611431068">
<p>Anatomical distribution of infections is described. Statistical analysis: χ<sup>2</sup> test. EAA, essential amino acid; <italic>NS</italic>, not significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Stratifying the entire study population in relation to 2 groups of etiology—that is, the group of ischemic stroke patients (n = 86) and the group of hemorrhagic stroke + anoxic coma + traumatic brain injury patients (n = 39)—we observed that within each group, the occurrence of infection in placebo patients was about 2-fold that of patients on EAAs. Indeed, in the ischemic stroke group, the infection rate was 54.7% in the placebo patients vs 27.5% in treated patients; in the other group, the infection rate was 70% in placebo patients and 37% in patients treated with EAAs.</p>
<p>With respect to the occurrence of infections over the second month of the hospital admission, 10 patients on placebo developed 1 infection, and 1 developed 3 infections. Among the treated group, 2 had another infection and 1 patient had 2 other episodes of infection. Intergroup differences in the recurrence of infection were not important (<italic>P</italic> = .26). Thus, over 2 months of hospital stay, the total number of infections was 50 in the placebo group and 27 in the treated patients.</p>
<p>The timing of infection was 15 ± 3 days after randomization in 45% of the patients and more than 20 days after randomization in the remaining 55% of the patients.</p>
<p>Antibiotics used for treating infections were cotrimoxazole (12.2%), penicillin and derivates (25.6%), quinolones (26.6%), amikacin (18.4%), imipenem (6.1%), teicoplanin (2%), cephalosporin (2%), and metronidazole (4.1%). Nonsignificant differences were found between the 2 subgroups with respect to the type of antibiotic being used.</p>
</sec>
<sec id="section13-0884533611431068">
<title>Changes in Variables During the Rehabilitation Period</title>
<p>Over time, both groups had significant and similar reductions from baseline of blood glucose (<italic>P</italic> &lt; .001), blood white cells (<italic>P</italic> = .005), neutrophils (<italic>P</italic> &lt; .0001), haptoglobin (<italic>P</italic> &lt; .002), fibrinogen (<italic>P</italic> = .003), and CRP (<italic>P</italic> &lt; .016). In contrast, the percentage of lymphocytes (<italic>P</italic> &lt; .0001) and FIM/DRS (<italic>P</italic> &lt; .001) increased in both groups. The average CRP values at discharge were above the normal upper limit (&lt;0.3 mg/dL; <xref ref-type="table" rid="table4-0884533611431068">Table 4</xref>). The changes in all these variables were more pronounced in the EAA group than in the placebo group, although the difference was not statistically significant.</p>
<table-wrap id="table4-0884533611431068" position="float">
<label>Table 4.</label>
<caption><p>Trends Over Time of the Variables Determined in the 2 Groups of Patients</p></caption>
<graphic alt-version="no" alternate-form-of="table4-0884533611431068" position="float" xlink:href="10.1177_0884533611431068-table4.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1"/>
<th align="center" colspan="3" rowspan="1">Placebo Group, Mean ± SD</th>
<th align="center" colspan="2" rowspan="1">EAA Group, Mean ± SD</th>
<th align="center" colspan="2" rowspan="1">Trend Over Time (<italic>P</italic> Level)</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Variables</th>
<th align="center" colspan="1" rowspan="1">Normal Values</th>
<th align="center" colspan="1" rowspan="1">Admission</th>
<th align="center" colspan="1" rowspan="1">Discharge</th>
<th align="center" colspan="1" rowspan="1">Admission</th>
<th align="center" colspan="1" rowspan="1">Discharge</th>
<th align="center" colspan="1" rowspan="1">Global</th>
<th align="center" colspan="1" rowspan="1">Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="8" rowspan="1"><bold>Anthropometric</bold></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Body weight, kg</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">72.3 ± 15.26</td>
<td colspan="1" rowspan="1">72.05 ± 14.47</td>
<td colspan="1" rowspan="1">71.63 ± 15.61</td>
<td colspan="1" rowspan="1">71.1 ± 14.72</td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1">Body mass index, kg/m<sup>2</sup></td>
<td colspan="1" rowspan="1"/>
<td colspan="1" rowspan="1">25.86 ± 4.6</td>
<td colspan="1" rowspan="1">25.8 ± 4.36</td>
<td colspan="1" rowspan="1">25.38 ± 4.55</td>
<td colspan="1" rowspan="1">25.20 ± 4.26</td>
<td colspan="1" rowspan="1">.2</td>
<td colspan="1" rowspan="1">.37</td>
</tr>
<tr>
<td colspan="8" rowspan="1"><bold>Blood</bold></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Erythrocyte sedimentation rate, first hour, mm</td>
<td colspan="1" rowspan="1">2–20</td>
<td colspan="1" rowspan="1">38.6 ± 30.3</td>
<td colspan="1" rowspan="1">32.84 ± 22.57</td>
<td colspan="1" rowspan="1">35.3 ± 30.3</td>
<td colspan="1" rowspan="1">31.27 ± 24.09</td>
<td colspan="1" rowspan="1">.14</td>
<td colspan="1" rowspan="1">.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Hemoglobin, g/dL</td>
<td colspan="1" rowspan="1">F &gt;12 M &gt;13</td>
<td colspan="1" rowspan="1">12.94 ± 1.9</td>
<td colspan="1" rowspan="1">12.8 ± 1.5</td>
<td colspan="1" rowspan="1">13.09 ± 1.2</td>
<td colspan="1" rowspan="1">12.9 ± 1.6</td>
<td colspan="1" rowspan="1">.26</td>
<td colspan="1" rowspan="1">.92</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Urea, mg/dL</td>
<td colspan="1" rowspan="1">20–40</td>
<td colspan="1" rowspan="1">39.8 ± 21.8</td>
<td colspan="1" rowspan="1">37 ± 16.1</td>
<td colspan="1" rowspan="1">40.9 ± 20.1</td>
<td colspan="1" rowspan="1">38.1 ± 13.6</td>
<td colspan="1" rowspan="1">.07</td>
<td colspan="1" rowspan="1">.94</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Creatinine, mg/dL</td>
<td colspan="1" rowspan="1">0.7–1.2</td>
<td colspan="1" rowspan="1">0.96 ± 0.3</td>
<td colspan="1" rowspan="1">1.01 ± 0.33</td>
<td colspan="1" rowspan="1">0.99 ± 0.26</td>
<td colspan="1" rowspan="1">0.98 ± 0.25</td>
<td colspan="1" rowspan="1">.15</td>
<td colspan="1" rowspan="1">.08</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Glucose, mg/dL</td>
<td colspan="1" rowspan="1">80–110</td>
<td colspan="1" rowspan="1">101.77 ± 26.1</td>
<td colspan="1" rowspan="1">90.8 ± 16.8</td>
<td colspan="1" rowspan="1">118.26 ± 43.2</td>
<td colspan="1" rowspan="1">101 ± 29</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">.19</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Total white cells, n/mm<sup>3</sup></td>
<td colspan="1" rowspan="1">4000–9000</td>
<td colspan="1" rowspan="1">6479 ± 1923</td>
<td colspan="1" rowspan="1">6194 ± 2487</td>
<td colspan="1" rowspan="1">6856 ± 1987</td>
<td colspan="1" rowspan="1">6177 ± 1711</td>
<td colspan="1" rowspan="1">.005</td>
<td colspan="1" rowspan="1">.24</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Neutrophils, %</td>
<td colspan="1" rowspan="1">50–70</td>
<td colspan="1" rowspan="1">60.19 ± 9.6</td>
<td colspan="1" rowspan="1">57.8 ± 9.45</td>
<td colspan="1" rowspan="1">59.85 ± 10.92</td>
<td colspan="1" rowspan="1">56 ± 10.4</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">.33</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Lymphocytes, %</td>
<td colspan="1" rowspan="1">20–40</td>
<td colspan="1" rowspan="1">27.3 ± 8.83</td>
<td colspan="1" rowspan="1">29.6 ± 8.97</td>
<td colspan="1" rowspan="1">27.8 ± 10.3</td>
<td colspan="1" rowspan="1">31.12 ± 10.6</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">.433</td>
</tr>
<tr>
<td colspan="1" rowspan="1">  Monocytes, %</td>
<td colspan="1" rowspan="1">2–12</td>
<td colspan="1" rowspan="1">8.73 ± 2.6</td>
<td colspan="1" rowspan="1">8.6 ± 2.64</td>
<td colspan="1" rowspan="1">9.23 ± 2.2</td>
<td colspan="1" rowspan="1">9.5 ± 2.33</td>
<td colspan="1" rowspan="1">.75</td>
<td colspan="1" rowspan="1">.31</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Albumin, g/dL</td>
<td colspan="1" rowspan="1">3.5–4.8</td>
<td colspan="1" rowspan="1">3.41 ± 0.54</td>
<td colspan="1" rowspan="1">3.47 ± 0.63</td>
<td colspan="1" rowspan="1">3.26 ± 0.56</td>
<td colspan="1" rowspan="1">3.44 ± 0.46</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Prealbumin, mg/dL</td>
<td colspan="1" rowspan="1">18–30</td>
<td colspan="1" rowspan="1">22.04 ± 5.9</td>
<td colspan="1" rowspan="1">22.66 ± 5.8</td>
<td colspan="1" rowspan="1">19.94 ± 5.39</td>
<td colspan="1" rowspan="1">20.44 ± 5.14</td>
<td colspan="1" rowspan="1">.22</td>
<td colspan="1" rowspan="1">.93</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Haptoglobin, mg/dL</td>
<td colspan="1" rowspan="1">420–902</td>
<td colspan="1" rowspan="1">195.1 ± 116.4</td>
<td colspan="1" rowspan="1">175 ± 90.4</td>
<td colspan="1" rowspan="1">193.7 ± 102.4</td>
<td colspan="1" rowspan="1">168 ± 73.2</td>
<td colspan="1" rowspan="1">.002</td>
<td colspan="1" rowspan="1">.80</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interleukin-6, pg/mL</td>
<td colspan="1" rowspan="1">1–7</td>
<td colspan="1" rowspan="1">11.52 ± 17.02</td>
<td colspan="1" rowspan="1">9.8 ± 9.03</td>
<td colspan="1" rowspan="1">19.92 ± 41.29</td>
<td colspan="1" rowspan="1">21.71 ± 79.9</td>
<td colspan="1" rowspan="1">.86</td>
<td colspan="1" rowspan="1">.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Fibrinogen, mg/dL</td>
<td colspan="1" rowspan="1">230–500</td>
<td colspan="1" rowspan="1">401.3 ± 101.4</td>
<td colspan="1" rowspan="1">373 ± 66</td>
<td colspan="1" rowspan="1">377 ± 91.93</td>
<td colspan="1" rowspan="1">358 ± 72.1</td>
<td colspan="1" rowspan="1">.003</td>
<td colspan="1" rowspan="1">.96</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Transferrin, mg/dL</td>
<td colspan="1" rowspan="1">150–300</td>
<td colspan="1" rowspan="1">204.23 ± 40.2</td>
<td colspan="1" rowspan="1">207.5 ± 41.5</td>
<td colspan="1" rowspan="1">205.16 ± 56</td>
<td colspan="1" rowspan="1">211 ± 47.5</td>
<td colspan="1" rowspan="1">.20</td>
<td colspan="1" rowspan="1">.94</td>
</tr>
<tr>
<td colspan="1" rowspan="1">C-reactive protein, mg/dL</td>
<td colspan="1" rowspan="1">&lt;0.3</td>
<td colspan="1" rowspan="1">1.48 ± 3.03</td>
<td colspan="1" rowspan="1">0.75 ± 0.98</td>
<td colspan="1" rowspan="1">1.27 ± 1.67</td>
<td colspan="1" rowspan="1">0.9 ± 1.8</td>
<td colspan="1" rowspan="1">.003</td>
<td colspan="1" rowspan="1">.75</td>
</tr>
<tr>
<td colspan="8" rowspan="1"><bold>Functional</bold></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Functional independence measure score/Disability Rating Scale</td>
<td colspan="1" rowspan="1">125</td>
<td colspan="1" rowspan="1">62.58 ± 27.9</td>
<td colspan="1" rowspan="1">80 ± 26.7</td>
<td colspan="1" rowspan="1">56.4 ± 28</td>
<td colspan="1" rowspan="1">77 ± 31.2</td>
<td colspan="1" rowspan="1">&lt;.016</td>
<td colspan="1" rowspan="1">.32</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0884533611431068">
<p>Statistical analysis: repeated measures analysis of variance. Trend over time: global = difference between admission and discharge; interaction = differences in trends between groups. EAA, essential amino acid; nv, normal value.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>During the rehabilitation period, baseline nutrition intakes, including ingested EAAs, were practically unchanged in the 2 groups, so that the patients’ body weight was preserved. This is an indicator that the nutrition intakes were adequate, particularly in proteins, iron, and zinc content, which play a major role in immune function<sup><xref ref-type="bibr" rid="bibr37-0884533611431068">37</xref></sup> (<xref ref-type="table" rid="table2-0884533611431068">Table 2</xref>).</p>
</sec>
<sec id="section14-0884533611431068">
<title>Risk-Identifying Variables</title>
<p>The univariate logistic analyses showed that albumin, prealbumin, transferrin, and CRP concentrations were statistically significantly associated with an increased risk of developing infection. ORs for patients at risk varied from 2.43 for transferrin to 4.17 for prealbumin (<xref ref-type="table" rid="table5-0884533611431068">Table 5</xref>). The stepwise procedure identified CRP (adjusted OR = 4.44; 95% CI, 1.74–11.32) and prealbumin (adjusted OR = 3.11; 95% CI, 1.30–7.46) as the risk factors most strongly predicting infections.</p>
<table-wrap id="table5-0884533611431068" position="float">
<label>Table 5.</label>
<caption><p>Results From Univariate Logistic Analysis Showing Risk-Individuating Variables Associated With an Increased Risk of Infection</p></caption>
<graphic alt-version="no" alternate-form-of="table5-0884533611431068" position="float" xlink:href="10.1177_0884533611431068-table5.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Variable</th>
<th align="center" colspan="1" rowspan="1">Odds Ratio</th>
<th align="center" colspan="1" rowspan="1">95% Confidence Interval</th>
<th align="center" colspan="1" rowspan="1"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Albumin (&lt;3.8 g/dL)</td>
<td colspan="1" rowspan="1">3.80</td>
<td colspan="1" rowspan="1">1.48–9.74</td>
<td colspan="1" rowspan="1">.005</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Prealbumin (&lt;20 mg/dL)</td>
<td colspan="1" rowspan="1">4.17</td>
<td colspan="1" rowspan="1">1.84–9.45</td>
<td colspan="1" rowspan="1">.001</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Transferrin (&lt;200 mg/dL)</td>
<td colspan="1" rowspan="1">2.43</td>
<td colspan="1" rowspan="1">1.16–5.10</td>
<td colspan="1" rowspan="1">.019</td>
</tr>
<tr>
<td colspan="1" rowspan="1">C-reactive protein (&gt;0.3 mg/dL)</td>
<td colspan="1" rowspan="1">3.80</td>
<td colspan="1" rowspan="1">1.71–8.44</td>
<td colspan="1" rowspan="1">.001</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section15-0884533611431068">
<title>Relationship Between Measured Variables and Functional Independence</title>
<p>At both admission and discharge, FIM/DRS was positively correlated with albumin, prealbumin, transferrin, and hemoglobin, whereas it was negatively associated with CRP. We also found that FIM/DRS at discharge was related to FIM/DRS on admission.</p>
<p>In multiple regression analysis, albumin and transferrin were the variables with the strongest association with FIM/DRS level at both admission and discharge (<xref ref-type="fig" rid="fig2-0884533611431068">Figure 2</xref>). The albumin level on admission was the strongest predictor of FIM/DRS at discharge (<xref ref-type="table" rid="table6-0884533611431068">Table 6</xref>).</p>
<fig id="fig2-0884533611431068" position="float">
<label>Figure 2.</label>
<caption><p>Correlations between circulating proteins (albumin and transferrin) and the patients’ functional independence measure (FIM) or disability rating scale (DRS), when appropriate. Values at the time of admission to and discharge from the rehabilitation unit are pooled together.</p></caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_0884533611431068-fig2.tif" xlink:type="simple"/>
</fig>
<table-wrap id="table6-0884533611431068" position="float">
<label>Table 6.</label>
<caption><p>Correlation Analysis Between Patients’ Functional Independence and Biohumoral Variables</p></caption>
<graphic alt-version="no" alternate-form-of="table6-0884533611431068" position="float" xlink:href="10.1177_0884533611431068-table6.tif" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="left" span="1"/>
</colgroup>
<thead>
<tr>
<th colspan="1" rowspan="1"/>
<th align="center" colspan="1" rowspan="1"><italic>r</italic><sup><xref ref-type="table-fn" rid="table-fn7-0884533611431068">a</xref></sup></th>
<th align="center" colspan="1" rowspan="1"><italic>P</italic> Value</th>
<th align="center" colspan="1" rowspan="1">Multiple Regression</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4" rowspan="1">FIM/DRS admission vs</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> albumin at admission</td>
<td colspan="1" rowspan="1">0.53</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> prealbumin at admission</td>
<td colspan="1" rowspan="1">0.35</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> transferrin at admission</td>
<td colspan="1" rowspan="1">0.42</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">Albumin (<italic>P</italic> &lt; .001)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRP at admission<sup><xref ref-type="table-fn" rid="table-fn8-0884533611431068">b</xref></sup></td>
<td colspan="1" rowspan="1">−0.46</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> hemoglobin at admission</td>
<td colspan="1" rowspan="1">0.35</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">Transferrin (<italic>P</italic> = .015)</td>
</tr>
<tr>
<td colspan="4" rowspan="1">FIM/DRS discharge vs</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> albumin at discharge</td>
<td colspan="1" rowspan="1">0.423</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">Albumin (<italic>P</italic> &lt; .001) Transferrin (<italic>P</italic> = .001)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> prealbumin at discharge</td>
<td colspan="1" rowspan="1">0.242</td>
<td colspan="1" rowspan="1">.008</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> transferrin at discharge</td>
<td colspan="1" rowspan="1">0.385</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1">Albumin (<italic>P</italic> &lt; .001) Transferrin (<italic>P</italic> = .001)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRP at discharge<sup><xref ref-type="table-fn" rid="table-fn8-0884533611431068">b</xref></sup></td>
<td colspan="1" rowspan="1">−0.217</td>
<td colspan="1" rowspan="1">.015</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> hemoglobin at discharge</td>
<td colspan="1" rowspan="1">0.16</td>
<td colspan="1" rowspan="1"><italic>NS</italic></td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="4" rowspan="1">FIM/DRS discharge vs</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> albumin at admission</td>
<td colspan="1" rowspan="1">0.400</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> prealbumin at admission</td>
<td colspan="1" rowspan="1">0.192</td>
<td colspan="1" rowspan="1">038</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> transferrin at admission</td>
<td colspan="1" rowspan="1">0.328</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> CRP at admission<sup><xref ref-type="table-fn" rid="table-fn8-0884533611431068">b</xref></sup></td>
<td colspan="1" rowspan="1">−0.362</td>
<td colspan="1" rowspan="1">&lt;.001</td>
<td colspan="1" rowspan="1"/>
</tr>
<tr>
<td colspan="1" rowspan="1"> FIM at admission</td>
<td colspan="1" rowspan="1">0.818</td>
<td colspan="1" rowspan="1">.001</td>
<td colspan="1" rowspan="1">Albumin (<italic>P</italic> &lt; .001)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0884533611431068">
<p>CRP, C-reactive protein; DRS, disability rating scale; FIM, functional independence measure; <italic>NS</italic>, not significant.</p>
</fn>
<fn id="table-fn7-0884533611431068">
<label>a</label>
<p>Pearson’s correlation coefficient.</p>
</fn>
<fn id="table-fn8-0884533611431068">
<label>b</label>
<p>Analysis performed on the log-transformed variable.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section16-0884533611431068" sec-type="discussion">
<title>Discussion</title>
<p>The study shows that supplementary EAAs may reduce the occurrence of infection in rehabilitation patients with BI by 23% over the first month of their stay in the hospital and by a total 30% over the entire period of rehabilitation (2 months). The study also indicated that serum concentrations of prealbumin &lt;20 mg/dL and CRP &gt;0.3 mg/dL can allow physicians to identify patients at high risk of future infection.</p>
<sec id="section17-0884533611431068">
<title>EAAs, Infection, and Body Inflammation</title>
<p>Despite the adoption of preventive measures, adequate nutrition (including daily ingestion of EAAs), and normal EAA plasma concentration, patients with BI receiving placebo had a high frequency of infections. This suggests that both normal ingestion and plasma concentration of EAAs may not be enough to limit the development of infection. It is probable that both the persistence of long-lasting inflammation<sup><xref ref-type="bibr" rid="bibr38-0884533611431068">38</xref></sup> and a further worsening of immune function following acute BI<sup><xref ref-type="bibr" rid="bibr10-0884533611431068">10</xref></sup> favor the occurrence of infections.</p>
<p>The persistence of inflammation at the time of admission to rehabilitation may reflect the persistence of an inflammatory response to brain ischemia<sup><xref ref-type="bibr" rid="bibr39-0884533611431068">39</xref>,<xref ref-type="bibr" rid="bibr40-0884533611431068">40</xref></sup> and/or postacute complications and hospitalization.</p>
<p>Indeed, in the post–acute phase of BI, patients usually develop 1 or more complications, causing a condition of chronic stress responsible for immunosuppression.<sup><xref ref-type="bibr" rid="bibr41-0884533611431068">41</xref></sup> This might help to explain why the rate of infections observed in rehabilitation patients receiving placebo was higher than that reported for individuals in ICUs.<sup><xref ref-type="bibr" rid="bibr2-0884533611431068">2</xref></sup></p>
<p>The data from the current study confirm the results of our recent investigation in which we found a 30% decrease in infections in elderly individuals undergoing intensive rehabilitation for diseases other than BI but who were treated with the same EAA formula and at the same dose as that used in this study.<sup><xref ref-type="bibr" rid="bibr7-0884533611431068">7</xref></sup> What is relevant in the present investigation is that the positive effects of EAAs occur when the amount of EAAs (as a percentage of total ingested amino acids) ingested daily is far above the normal values (around 30% in our laboratory). In treated patients, the ingestion of high amounts of EAAs could seem in conflict with normal EAA plasma concentrations. This can be reconciled when considering that the ingestion of EAAs is followed by increased EAA plasma concentration that returns to a preingestion concentration within 4 hours (R. Aquilani, unpublished data), whereas in this study, patients’ blood samples for amino acid determination were drawn in the morning after overnight fasting, as indicated in the experimental section.</p>
<p>The decrease of infection rate in the treated group was probably due to the actions of EAAs on immune cells. Indeed, EAAs can potentiate a patient’s immune response through at least 2 mechanisms: inducing protein synthesis in immune cells and directly influencing some metabolic pathways involved in immune function.</p>
<p>Protein synthesis<sup><xref ref-type="bibr" rid="bibr42-0884533611431068">42</xref>-<xref ref-type="bibr" rid="bibr44-0884533611431068">44</xref></sup> is crucial to increase bacterial killing, lymphocyte proliferation, macrophage phagocytosis, and antibody and cytokine production.<sup><xref ref-type="bibr" rid="bibr26-0884533611431068">26</xref></sup> It is interesting that the increase observed in blood lymphocyte percentage during the rehabilitation period was more pronounced, albeit not significantly so, in the treated patients (+18%) than in the placebo recipients (+4.4%). The decrease in blood white cell count was greater in treated patients (–18%) than in the placebo recipients (–4.4%). The improvement in lymphocyte counts found in this study is in line with that observed in a recent investigation carried out in individuals in an ICU treated with the same formula, at the same dose as that used in the current study.<sup><xref ref-type="bibr" rid="bibr45-0884533611431068">45</xref></sup></p>
<p>Some amino acids contained in the formula can directly and specifically affect some metabolic pathways involved in immunity. For instance, cysteine is a substrate essential for glutathione metabolism and the redox potential of immune cells<sup><xref ref-type="bibr" rid="bibr46-0884533611431068">46</xref></sup>; methionine (and cysteine) is essential for the synthesis of nucleic bases<sup><xref ref-type="bibr" rid="bibr47-0884533611431068">47</xref></sup> and, therefore, cell proliferation and differentiation.</p>
<p>The formula used in this study does not contain glutamine, the most important amino acid for immune activity.<sup><xref ref-type="bibr" rid="bibr26-0884533611431068">26</xref></sup> Nevertheless, we observed in our laboratory (R. Aquilani, unpublished data) that healthy individuals given supplementation with 8 g of the formula had a 10% increase in their plasma glutamine concentrations for 3 hours. The increase was not accompanied by an impairment of plasma arginine concentration, another important amino acid for immune function.<sup><xref ref-type="bibr" rid="bibr26-0884533611431068">26</xref></sup> It is likely that leucine, the main amino acid of the formula, may stimulate glutamine formation.<sup><xref ref-type="bibr" rid="bibr48-0884533611431068">48</xref></sup></p>
<p>The study indicates that patients with BI are discharged with a subclinical inflammation even though of lower grade in comparison to that observed at admission to rehabilitation. This suggests that 5 to 6 months after the index event, inflammatory processes and an evoked immune response are still active. Indeed, high levels of IL-6 are produced by pathogen-activated immune cells.<sup><xref ref-type="bibr" rid="bibr49-0884533611431068">49</xref></sup> In turn, IL-6 mediates the immune system response, for instance, by inducing immunoglobulin formation in B lymphocytes and differentiation of cytotoxic cells.<sup><xref ref-type="bibr" rid="bibr49-0884533611431068">49</xref></sup></p>
<p>It is relevant to this study that elevated levels of IL-6 increase the need for protein synthesis and, consequently, for EAA availability. At a first glance, the inflammation, both at admission and discharge, seems not to have evoked an acute response given the normal values of acute reactant proteins (fibrinogen, haptoglobin). However, this is misleading because the reduction at discharge of “normal” reactant proteins suggests that actually the levels of these proteins at admission were higher than they would have been in the preevent period.</p>
<p>The gradual reduction of inflammation over time could explain the significant decrease in blood glucose levels during rehabilitation; during rehabilitation, the reduction of glucose means a decrease of liver gluconeogenic activity, one of the markers of the acute phase response. Very likely, the higher blood glucose levels observed in the EAA group at admission in comparison with those in the placebo group reflected a more marked acute phase response before admission for rehabilitation.</p>
</sec>
<sec id="section18-0884533611431068">
<title>Serum Proteins as Risk Factors for Future Infection</title>
<p>The study indicates that serum prealbumin &lt;20 mg/dL and CRP &gt;0.3 mg/dL are the risk factors with the strongest potential to predict the development of a future infection.</p>
<p>Prealbumin is a protein synthesized by the liver and secreted into the circulation. It is a negative reactant protein during metabolic stress from trauma, injury, infection, and body systemic inflammation and is negatively influenced by inadequate nutrition. Because of its short half-life (2–3 days), prealbumin levels rapidly reflect changes in hepatic protein synthesis.<sup><xref ref-type="bibr" rid="bibr50-0884533611431068">50</xref></sup> It is possible that the importance of prealbumin as a risk factor for infection may derive just from its ability to reflect 2 effects simultaneously: the early shift of liver protein synthesis induced by the acute phase response and inadequacy of nutrition that usually occurs with the acute phase response.</p>
<p>CRP is a positive reactant protein of the acute phase response following acute injury, infection, and trauma. High CRP levels reflect inflammation. This protein is synthesised in the liver under the influence of increased IL-6 production.<sup><xref ref-type="bibr" rid="bibr49-0884533611431068">49</xref></sup> The importance of elevated CRP as a risk factor for infection confirms the finding of our previous investigation.<sup><xref ref-type="bibr" rid="bibr7-0884533611431068">7</xref></sup></p>
<p>The value of serum albumin concentration &lt;3.8 g/dL and transferrin &lt;200 mg/dL as factors predicting infection should not be underestimated, particularly when measures of prealbumin and CRP are not feasible.</p>
<p>The patients’ baseline reduction of albumin (&lt;3.5 g/dL) can be explained by the persistence of the shift of liver protein synthesis primed by the acute phase response and, concomitantly, a possible inadequate response to nutrition in the acute and post–acute periods after the BI.<sup><xref ref-type="bibr" rid="bibr51-0884533611431068">51</xref></sup></p>
<p>It is of clinical interest that a cutoff level of albumin &lt;3.8 g/dL to identify patients at increased risk of infection is higher than the normal lower value of our laboratory (3.5 g/dL). In this respect, the present study seems to confirm that an albumin concentration of 3.5 g/dL<sup><xref ref-type="bibr" rid="bibr52-0884533611431068">52</xref></sup> may represent a clinically suboptimal level. Indeed, albumin &lt;3.8 g/dL better predicts future loss of skeletal mass (sarcopenia) and poor functioning in older individuals.<sup><xref ref-type="bibr" rid="bibr52-0884533611431068">52</xref></sup></p>
<p>Last, normal transferrin levels mean a normal capacity of binding iron, which is essential for immunocompetency.<sup><xref ref-type="bibr" rid="bibr37-0884533611431068">37</xref></sup></p>
</sec>
<sec id="section19-0884533611431068">
<title>Relationship Between Variables and Functional Independence</title>
<p>Albumin and transferrin levels had the strongest association with FIM/DRS both at admission and discharge of the patients. Importantly, 3 months after the acute event, the albumin concentration at admission had the highest predictive power for FIM/DRS at discharge. This confirms that patients’ protein status, as result of nutrition/body inflammation state, plays a crucial role in brain repair.<sup><xref ref-type="bibr" rid="bibr53-0884533611431068">53</xref>-<xref ref-type="bibr" rid="bibr57-0884533611431068">57</xref></sup></p>
<p>Circulating proteins and anatomical and functional damage to the brain mutually influence each other. Indeed, the levels of serum protein are largely affected by acute phase response primed by vascular or traumatic insult to the brain,<sup><xref ref-type="bibr" rid="bibr53-0884533611431068">53</xref></sup> and, in turn, circulating proteins influence both repair processes and functional reactivation of damaged areas of the brain.<sup><xref ref-type="bibr" rid="bibr53-0884533611431068">53</xref></sup> Experimental investigations have demonstrated a beneficial effect of albumin on brain activity. Moderate- to high-dose human albumin therapy provides neuroprotection in animal models of cerebral ischemia and traumatic BI.<sup><xref ref-type="bibr" rid="bibr58-0884533611431068">58</xref></sup> The benefit of albumin to the damaged brain may be due to 1 or more properties of the protein, including free radical scavenging, colloid osmotic pressure favoring blood perfusion, platelet function inhibition and antithrombotic effects, capillary membrane permeability, and the binding and transport of molecules, including zinc.<sup><xref ref-type="bibr" rid="bibr59-0884533611431068">59</xref>,<xref ref-type="bibr" rid="bibr60-0884533611431068">60</xref></sup> Even in healthy people, the levels of albumin are important for functional status. Indeed, observational studies found that the circulating protein influences physical performance even among nondisabled persons<sup><xref ref-type="bibr" rid="bibr61-0884533611431068">61</xref></sup> and is positively related to functional status.<sup><xref ref-type="bibr" rid="bibr62-0884533611431068">62</xref>,<xref ref-type="bibr" rid="bibr63-0884533611431068">63</xref></sup> Lower levels of albumin are predictive of a greater decline in functional status.<sup><xref ref-type="bibr" rid="bibr61-0884533611431068">61</xref></sup></p>
<p>Normal levels of circulating transferrin are essential for binding brain iron to allow efflux of the mineral from the brain. An excess of free iron in brain structures occurs following neuronal damage after cerebral ischemia and trauma and contributes greatly to the progression of stroke and worsening outcome.<sup><xref ref-type="bibr" rid="bibr64-0884533611431068">64</xref></sup></p>
<p>The continued positive association of transferrin levels with functional status at the time of the patients’ discharge suggests that 5 months after an acute event, the neurocognitive recovery of patients is influenced by brain iron metabolism.</p>
<p>Although prealbumin, hemoglobin, and CRP levels did not enter the multiple correlations in the model, we believe they merit some comments.</p>
<p>The positive correlation between prealbumin levels and patients’ independence enhances the importance of adequate nutrition for neuromotor and cognitive recovery.<sup><xref ref-type="bibr" rid="bibr53-0884533611431068">53</xref>-<xref ref-type="bibr" rid="bibr57-0884533611431068">57</xref></sup> In contrast to our previous studies on stroke patients, this investigation failed to demonstrate a significant improvement in patients’ disability following supplementation with EAAs in comparison to patients given a placebo. The discrepancy is probably the result of a different study design. In fact, in previous investigations, patients were enrolled within 30 days after the acute event, which is the period in which potentially 80% of future total neurological recovery occurs. In this study, patients with stroke, who represented the vast majority of the population, were enrolled later (88 days) after the index event. Difficulty of EAAs to enter brain structures can be excluded given that these substrates enter as rapidly as glucose, particularly for blood-brain barrier damage.<sup><xref ref-type="bibr" rid="bibr56-0884533611431068">56</xref>,<xref ref-type="bibr" rid="bibr57-0884533611431068">57</xref></sup></p>
<p>By providing an oxygen supply to cerebral and extra-cerebral structures, the hemoglobin concentration favors patients’ functional independence. The brain’s requirement for oxygen is further increased under ischemic conditions.<sup><xref ref-type="bibr" rid="bibr64-0884533611431068">64</xref></sup></p>
<p>The negative relation of CRP with FIM/DRS suggests that subclinical body inflammation has a negative impact on the recovery of functional independence.</p>
<p>The study also indicates the importance of the level of neuromotor-cognitive function at admission for the patients’ functional status at the end of rehabilitation.</p>
</sec>
</sec>
<sec id="section20-0884533611431068">
<title>Clinical Implications</title>
<p>The study suggests that certain factors may be useful for the clinical practice of patients with BI admitted at about 3 months after the index event.</p>
<p>First, it is possible to identify individuals with BI at increased risk of future infection by measuring the serum levels of prealbumin and CRP. If this is not feasible, albumin and transferrin concentrations can be useful.</p>
<p>Second, at 3 months after an acute event, it is useful to monitor patients’ protein intake and circulating proteins, including CRP, given that these factors affect the recovery of functional status.</p>
<p>Third, at discharge from rehabilitation, CRP should always be determined, not only to predict the risk of developing infection at home but also because elevated levels of the protein per se affect both life and functional prognosis. Persistently high levels of CRP may be particularly ominous for stroke-surviving individuals. Because the protein contributes directly to the progression of atherosclerosis and the proliferation of cardiovascular events,<sup><xref ref-type="bibr" rid="bibr65-0884533611431068">65</xref></sup> high CRP after a first cerebrovascular event can predict further adverse cardiovascular events and recurrent strokes.<sup><xref ref-type="bibr" rid="bibr66-0884533611431068">66</xref></sup> It has been reported that carotid artery plaques are less stable in those with elevated CRP.<sup><xref ref-type="bibr" rid="bibr67-0884533611431068">67</xref></sup> High CRP can slow the functional recovery of patients with BI because the protein diminishes angiogenesis, a key compensatory mechanism in chronic ischemia,<sup><xref ref-type="bibr" rid="bibr68-0884533611431068">68</xref></sup> and augments the endothelial cell production of IL-6.<sup><xref ref-type="bibr" rid="bibr68-0884533611431068">68</xref></sup></p>
<p>These considerations should prompt physicians and general practitioners to reduce the risk of infection as much as possible, treat an infection immediately when it occurs, and achieve total resolution of inflammation primed by infection.</p>
<p>This study highlights the importance of improving patients’ functional status as much as possible within the first days/weeks after the acute event. We believe that one possibility for favoring patients’ recovery in this context may be better monitoring and treatment of metabolic alterations.</p>
</sec>
<sec id="section21-0884533611431068">
<title>Limitations</title>
<p>This study has some unresolved issues that should be faced with appropriate investigations.</p>
<p>We did not consider the effects of EAAs on the prevention of a specific infection (urinary, respiratory, or gastrointestinal).</p>
<p>The study addressed the prevention of infection in a large population with BI independently of the type of primary disease (cerebrovascular, traumatic, or cardiac origin). At first glance, this may seem to be a limitation of the study. However, we believe that this was actually a strength of the study. In fact, our intent was to control infection independently of the underlying disease. Our starting point was that the causes of BI have a common denominator consisting of injury-induced immune dysfunction/suppression that can be further aggravated by postacute complications. Substances such as EAAs, which are potentially able to act on immune cells, could, therefore, favor reduction of infection independently of the primary disorder. This is clearly indicated in the study by the occurrence of infection that nearly halved in patients supplemented with EAAs in comparison to those on placebo, independently of the etiology group. Thus, the study suggests that each brain-injured population may benefit from EAA supplementation. In this study, we did not directly measure the activity of EAAs on immune cell function. For instance, determination of T lymphocyte subpopulations would have strengthened the discussion.</p>
<p>Interestingly, instead of a mixture of non-EAAs, we chose maltodextrin as the placebo because this polysaccharide has a potential immunomodulatory effect. The study demonstrated that EAAs are superior to maltodextrin in reducing infection. If we had chosen non-EAAs as placebo, we would have undoubtedly shown the superiority of EAAs to reduce the rate of infection, given that increased immunocompetence relies on a huge activity of protein synthesis. This occurs with EAAs only. Thus, we believed that a more potent competitor against EAAs would have been a substrate with a potential immunomodulatory effect.<sup><xref ref-type="bibr" rid="bibr69-0884533611431068">69</xref>-<xref ref-type="bibr" rid="bibr71-0884533611431068">71</xref></sup></p>
</sec>
<sec id="section22-0884533611431068">
<title>Bacterial Ecology and Financial Considerations</title>
<p>This study indicates that EAAs, by reducing the occurrence of infection, can contribute considerably to lowering the selection of more aggressive pathogens as well as antibiotic use and resistance in the rehabilitation context. Over 1 year, we spared 230 days of antibiotic therapy among 125 patients.</p>
<p>Appropriate studies are necessary to quantify both direct and indirect cost-savings from the use of EAA supplementation.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533611431068">
<label>1.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mylotte</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Graham</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Kahler</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Young</surname><given-names>BL</given-names></name>
<name name-style="western"><surname>Goodnough</surname><given-names>S</given-names></name>
</person-group>. <article-title>Impact of nosocomial infection on length of stay and functional improvement among patients admitted to an acute rehabilitation unit</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2001</year>;<volume>22</volume>(<issue>2</issue>):<fpage>83</fpage>-<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr2-0884533611431068">
<label>2.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Frontera</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Fernandez</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Schmidt</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Impact of nosocomial infectious complications after subarachnoid haemorrhage</article-title>. <source>Neurosurgery</source>. <year>2008</year>;<volume>62</volume>(<issue>1</issue>):<fpage>80</fpage>-<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr3-0884533611431068">
<label>3.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kuptniratsaikul</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Kovindha</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Suethanapornkul</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Manimmanakorn</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Archongka</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Complications during the rehabilitation period in Thai patients with stroke: a multicenter prospective study</article-title>. <source>Am J Phys Med Rehabil</source>. <year>2009</year>;<volume>88</volume>(<issue>2</issue>):<fpage>92</fpage>-<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr4-0884533611431068">
<label>4.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Roth</surname><given-names>EJ</given-names></name>
<name name-style="western"><surname>Lovell</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Harvey</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Heinemann</surname><given-names>AW</given-names></name>
<name name-style="western"><surname>Semik</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Diaz</surname><given-names>S</given-names></name>
</person-group>. <article-title>Incidence of and risk factors for medical complications during stroke rehabilitation</article-title>. <source>Stroke</source>. <year>2001</year>;<volume>32</volume>(<issue>2</issue>):<fpage>523</fpage>-<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr5-0884533611431068">
<label>5.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fugazza</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Iadarola</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>The persistence of hyper catabolic state in rehabilitation patients with complicated head injury</article-title>. <source>Eur Med Phys</source>. <year>1998</year>;<volume>34</volume>(<issue>3</issue>):<fpage>125</fpage>-<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr6-0884533611431068">
<label>6.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kalra</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Wilson</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Roots</surname><given-names>P</given-names></name>
</person-group>. <article-title>Medical complications during stroke rehabilitation</article-title>. <source>Stroke</source>. <year>1995</year>;<volume>26</volume>(<issue>6</issue>):<fpage>990</fpage>-<lpage>994</lpage>.</citation>
</ref>
<ref id="bibr7-0884533611431068">
<label>7.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Zuccarelli</surname><given-names>GC</given-names></name>
<name name-style="western"><surname>Dioguardi</surname><given-names>FS</given-names></name>
<etal/>
</person-group>. <article-title>Effects of oral amino acid supplementation on long-term-care-acquired infections in elderly patients</article-title>. <source>Arch Gerontol Geriatr</source>. <year>2011</year>;<volume>52</volume>(<issue>3</issue>):<fpage>e123</fpage>-<lpage>e128</lpage>.</citation>
</ref>
<ref id="bibr8-0884533611431068">
<label>8.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Berenholtz</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Pronovost</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Lipsett</surname><given-names>PA</given-names></name>
<etal/>
</person-group>. <article-title>Eliminating catheter-related bloodstream infections in the intensive care unit</article-title>. <source>Crit Care Med</source>. <year>2004</year>;<volume>32</volume>(<issue>10</issue>):<fpage>2014</fpage>-<lpage>2020</lpage>.</citation>
</ref>
<ref id="bibr9-0884533611431068">
<label>9.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mermel</surname><given-names>LA</given-names></name>
</person-group>. <article-title>Prevention of intravascular catheter-related infections</article-title>. <source>Ann Intern Med</source>. <year>2000</year>;<volume>133</volume>(<issue>5</issue>):<fpage>395</fpage>.</citation>
</ref>
<ref id="bibr10-0884533611431068">
<label>10.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Calder</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Immunonutrition in surgical and critically ill patients [review]</article-title>. <source>Br J Nutr</source>. <year>2007</year>;<volume>98</volume>(<issue>suppl 1</issue>):<fpage>S133</fpage>-<lpage>S139</lpage>.</citation>
</ref>
<ref id="bibr11-0884533611431068">
<label>11.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Meisel</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Schwab</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Prass</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Meisel</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Dirnagl</surname><given-names>U</given-names></name>
</person-group>. <article-title>Central nervous system injury-induced immune deficiency syndrome [review]</article-title>. <source>Nat Rev Neurosci</source>. <year>2005</year>;<volume>6</volume>(<issue>10</issue>):<fpage>775</fpage>-<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr12-0884533611431068">
<label>12.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Esper</surname><given-names>DH</given-names></name>
<name name-style="western"><surname>Coplin</surname><given-names>WM</given-names></name>
<name name-style="western"><surname>Carhuapoma</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Energy expenditure in patients with nontraumatic intracranial hemorrhage</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2006</year>;<volume>30</volume>(<issue>2</issue>):<fpage>71</fpage>-<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr13-0884533611431068">
<label>13.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Badjatia</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Fernandez</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Schlossberg</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. <article-title>Relationship between energy balance and complications after subarachnoid hemorrhage</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>(<issue>1</issue>):<fpage>64</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr14-0884533611431068">
<label>14.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Yoshimoto</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Tanaka</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Hoya</surname><given-names>K</given-names></name>
</person-group>. <article-title>Acute systemic inflammatory response syndrome in subarachnoid hemorrhage</article-title>. <source>Stroke</source>. <year>2001</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1989</fpage>-<lpage>1993</lpage>.</citation>
</ref>
<ref id="bibr15-0884533611431068">
<label>15.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dhar</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Diringer</surname><given-names>MN</given-names></name>
</person-group>. <article-title>The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage</article-title>. <source>Neurocrit Care</source>. <year>2008</year>;<volume>8</volume>(<issue>3</issue>):<fpage>404</fpage>-<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr16-0884533611431068">
<label>16.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mokart</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Capo</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Blache</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer</article-title>. <source>Br J Surg</source>. <year>2002</year>;<volume>89</volume>(<issue>11</issue>):<fpage>1450</fpage>-<lpage>1456</lpage>.</citation>
</ref>
<ref id="bibr17-0884533611431068">
<label>17.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Nielsen</surname><given-names>HJ</given-names></name>
</person-group>. <article-title>Detrimental effects of perioperative blood transfusion [review]</article-title>. <source>Br J Surg</source>. <year>1995</year>;<volume>82</volume>(<issue>5</issue>):<fpage>582</fpage>-<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr18-0884533611431068">
<label>18.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sorbello</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Dewey</surname><given-names>HM</given-names></name>
<name name-style="western"><surname>Churilov</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Very early mobilisation and complications in the first 3 months after stroke: further results from phase II of A Very Early Rehabilitation Trial (AVERT)</article-title>. <source>Cerebrovasc Dis</source>. <year>2009</year>;<volume>28</volume>(<issue>4</issue>):<fpage>378</fpage>-<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr19-0884533611431068">
<label>19.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hill</surname><given-names>AG</given-names></name>
<name name-style="western"><surname>Hill</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Metabolic response to severe injury [review]</article-title>. <source>Br J Surg</source>. <year>1998</year>;<volume>85</volume>(<issue>7</issue>):<fpage>884</fpage>-<lpage>890</lpage>.</citation>
</ref>
<ref id="bibr20-0884533611431068">
<label>20.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Touho</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Karasawa</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Shishido</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Morisako</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Shibamoto</surname><given-names>K</given-names></name>
</person-group>. <article-title>Hypermetabolism in the acute stage of hemorrhagic cerebrovascular disease</article-title>. <source>J Neurosurg</source>. <year>1990</year>;<volume>72</volume>(<issue>5</issue>):<fpage>710</fpage>-<lpage>714</lpage>.</citation>
</ref>
<ref id="bibr21-0884533611431068">
<label>21.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Martindale</surname><given-names>RG</given-names></name>
<name name-style="western"><surname>Cresci</surname><given-names>G</given-names></name>
</person-group>. <article-title>Preventing infectious complications with nutrition intervention [review]</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2005</year>;<volume>29</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>S53</fpage>-<lpage>S56</lpage>.</citation>
</ref>
<ref id="bibr22-0884533611431068">
<label>22.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Keel</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Trentz</surname><given-names>O</given-names></name>
</person-group>. <article-title>Pathophysiology of polytrauma [review]</article-title>. <source>Injury</source>. <year>2005</year>;<volume>36</volume>(<issue>6</issue>):<fpage>691</fpage>-<lpage>709</lpage>.</citation>
</ref>
<ref id="bibr23-0884533611431068">
<label>23.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Long</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Fryburg</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Barrett</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>The regulation of body and skeletal muscle protein metabolism by hormones and amino acids</article-title>. <source>J Nutr</source>. <year>2006</year>;<volume>136</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>212S</fpage>-<lpage>217S</lpage>.</citation>
</ref>
<ref id="bibr24-0884533611431068">
<label>24.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Vila</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Castillo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Dávalos</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Chamorro</surname><given-names>A</given-names></name>
</person-group>. <article-title>Proinflammatory cytokines and early neurological worsening in ischemic stroke</article-title>. <source>Stroke</source>. <year>2000</year>;<volume>31</volume>(<issue>10</issue>):<fpage>2325</fpage>-<lpage>2329</lpage>.</citation>
</ref>
<ref id="bibr25-0884533611431068">
<label>25.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Silva</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Leira</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Tejada</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Lainez</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Castillo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Dávalos</surname><given-names>A</given-names></name>
</person-group>; <collab xlink:type="simple">Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society</collab>. <article-title>Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage</article-title>. <source>Stroke</source>. <year>2005</year>;<volume>36</volume>(<issue>1</issue>):<fpage>86</fpage>-<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr26-0884533611431068">
<label>26.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Roth</surname><given-names>E</given-names></name>
</person-group>. <article-title>Immune and cell modulation by amino acids [review]</article-title>. <source>Clin Nutr</source>. <year>2007</year>;<volume>26</volume>(<issue>5</issue>):<fpage>535</fpage>-<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr27-0884533611431068">
<label>27.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lesourd</surname><given-names>B</given-names></name>
</person-group>. <article-title>Protein undernutrition as the major cause of decreased immune function in the elderly: clinical and functional implications [review]</article-title>. <source>Nutr Rev</source>. <year>1995</year>;<volume>53</volume>(<issue>4, pt 2</issue>):<fpage>S86</fpage>-<lpage>S91</lpage>; <comment>discussion S92-S94</comment>.</citation>
</ref>
<ref id="bibr28-0884533611431068">
<label>28.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Chandra</surname><given-names>RK</given-names></name>
</person-group>. <article-title>Nutrition and the immune system from birth to old age [review]</article-title>. <source>Eur J Clin Nutr</source>. <year>2002</year>;<volume>56</volume>(<issue>suppl 3</issue>):<fpage>S73</fpage>-<lpage>S76</lpage>.</citation>
</ref>
<ref id="bibr29-0884533611431068">
<label>29.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Chumlea</surname><given-names>WC</given-names></name>
<name name-style="western"><surname>Roche</surname><given-names>AF</given-names></name>
<name name-style="western"><surname>Steinbaugh</surname><given-names>ML</given-names></name>
</person-group>. <article-title>Estimating stature from knee height for persons 60 to 90 years of age</article-title>. <source>J Am Geriatr Soc</source>. <year>1985</year>;<volume>33</volume>(<issue>2</issue>): <fpage>116</fpage>-<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr30-0884533611431068">
<label>30.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Keith</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Granger</surname><given-names>CV</given-names></name>
<name name-style="western"><surname>Hamilton</surname><given-names>BB</given-names></name>
<name name-style="western"><surname>Sherwin</surname><given-names>FS</given-names></name>
</person-group>. <article-title>The functional independence measure: a new tool for rehabilitation</article-title>. In: <person-group person-group-type="editor">
<name name-style="western"><surname>Eisenberg</surname><given-names>MG</given-names></name>
<name name-style="western"><surname>Grzesiak</surname><given-names>RC</given-names></name>
</person-group>, eds. <source>Advances in Clinical Rehabilitation</source>. <volume>Vol I</volume>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <volume>1987</volume>:<fpage>6</fpage>-<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr31-0884533611431068">
<label>31.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Gouvier</surname><given-names>WD</given-names></name>
<name name-style="western"><surname>Blanton</surname><given-names>PD</given-names></name>
<name name-style="western"><surname>LaPorte</surname><given-names>KK</given-names></name>
<name name-style="western"><surname>Nepomuceno</surname><given-names>C</given-names></name>
</person-group>. <article-title>Reliability and validity of the Disability Rating Scale and the Levels of Cognitive Functioning Scale in monitoring recovery from severe head injury</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1987</year>;<volume>68</volume>:<fpage>94</fpage>-<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr32-0884533611431068">
<label>32.</label>
<citation citation-type="book" xlink:type="simple">
<source>Tabelle di composizione degli alimenti</source>. <comment>Istituto superiore nazionale della nutrizione</comment>; <publisher-loc>Rome, Italy</publisher-loc>, <year>1989</year>.</citation>
</ref>
<ref id="bibr33-0884533611431068">
<label>33.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Tramarin</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Pedretti</surname><given-names>RF</given-names></name>
<etal/>
</person-group>. <article-title>Despite good compliance, very low fat diet alone does not achieve recommended cholesterol goals in outpatients with coronary heart disease</article-title>. <source>Eur Heart J</source>. <year>1999</year>;<volume>20</volume>(<issue>14</issue>):<fpage>1020</fpage>-<lpage>1029</lpage>.</citation>
</ref>
<ref id="bibr34-0884533611431068">
<label>34.</label>
<citation citation-type="confproc" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rello</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Paiva</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Baraibar</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <conf-name>International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia [review]</conf-name>. <source>Chest</source>. <conf-date>2001</conf-date>;<volume>120</volume>(<issue>3</issue>):<fpage>955</fpage>-<lpage>970</lpage>.</citation>
</ref>
<ref id="bibr35-0884533611431068">
<label>35.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wartenberg</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Schmidt</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Claassen</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Impact of medical complications on outcome after subarachnoid hemorrhage</article-title>. <source>Crit Care Med</source>. <year>2006</year>;<volume>34</volume>(<issue>3</issue>):<fpage>617</fpage>-<lpage>623</lpage>; <comment>quiz 624</comment>.</citation>
</ref>
<ref id="bibr36-0884533611431068">
<label>36.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hugonnet</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sax</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Eggimann</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Chevrolet</surname><given-names>JC</given-names></name>
<name name-style="western"><surname>Pittet</surname><given-names>D</given-names></name>
</person-group>. <article-title>Nosocomial bloodstream infection and clinical sepsis</article-title>. <source>Emerg Infect Dis</source>. <year>2004</year>;<volume>10</volume>(<issue>1</issue>):<fpage>76</fpage>-<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr37-0884533611431068">
<label>37.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Molls</surname><given-names>RR</given-names></name>
<name name-style="western"><surname>Ahluwalia</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Mastro</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Smiciklas-Wright</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Handte</surname><given-names>GC</given-names></name>
</person-group>. <article-title>Nutritional status predicts primary subclasses of T cells and the lymphocyte proliferation response in healthy older women</article-title>. <source>J Nutr</source>. <year>2005</year>;<volume>135</volume>(<issue>11</issue>):<fpage>2644</fpage>-<lpage>2650</lpage>.</citation>
</ref>
<ref id="bibr38-0884533611431068">
<label>38.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Gussekloo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Schaap</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Frölich</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Blauw</surname><given-names>GJ</given-names></name>
<name name-style="western"><surname>Westendorp</surname><given-names>RG</given-names></name>
</person-group>. <article-title>C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2000</year>;<volume>20</volume>(<issue>4</issue>):<fpage>1047</fpage>-<lpage>1051</lpage>.</citation>
</ref>
<ref id="bibr39-0884533611431068">
<label>39.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Vila</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Castillo</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Dávalos</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Chamorro</surname><given-names>A</given-names></name>
</person-group>. <article-title>Proinflammatory cytokines and early neurological worsening in ischemic stroke</article-title>. <source>Stroke</source>. <year>2000</year>;<volume>31</volume>(<issue>10</issue>):<fpage>2325</fpage>-<lpage>2329</lpage>.</citation>
</ref>
<ref id="bibr40-0884533611431068">
<label>40.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Winbeck</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Poppert</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Etgen</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Conrad</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Sander</surname><given-names>D</given-names></name>
</person-group>. <article-title>Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke</article-title>. <source>Stroke</source>. <year>2002</year>;<volume>33</volume>(<issue>10</issue>):<fpage>2459</fpage>-<lpage>2464</lpage>.</citation>
</ref>
<ref id="bibr41-0884533611431068">
<label>41.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Tracey</surname><given-names>KJ</given-names></name>
</person-group>. <article-title>The inflammatory reflex</article-title>. <source>Nature</source>. <year>2002</year>;<volume>420</volume>(<issue>6917</issue>): <fpage>853</fpage>-<lpage>859</lpage>.</citation>
</ref>
<ref id="bibr42-0884533611431068">
<label>42.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fafournoux</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Bruhat</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Jousse</surname><given-names>C</given-names></name>
</person-group>. <article-title>Amino acid regulation of gene expression [review]</article-title>. <source>Biochem J</source>. <year>2000</year>;<volume>351</volume>(<issue>pt 1</issue>):<fpage>1</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr43-0884533611431068">
<label>43.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lynch</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Patson</surname><given-names>BJ</given-names></name>
<name name-style="western"><surname>Anthony</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Vaval</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Jefferson</surname><given-names>LS</given-names></name>
<name name-style="western"><surname>Vary</surname><given-names>TC</given-names></name>
</person-group>. <article-title>Leucine is a direct-acting nutrient signal that regulates protein synthesis in adipose tissue</article-title>. <source>Am J Physiol Endocrinol Metab</source>. <year>2002</year>;<volume>283</volume>(<issue>3</issue>):<fpage>E503</fpage>-<lpage>E513</lpage>.</citation>
</ref>
<ref id="bibr44-0884533611431068">
<label>44.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rennie</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Bohé</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Wackerhage</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Greenhaff</surname><given-names>P</given-names></name>
</person-group>. <article-title>Branched-chain amino acids as fuels and anabolic signals in human muscle [review]</article-title>. <source>J Nutr</source>. <year>2006</year>;<volume>136</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>264S</fpage>-<lpage>268S</lpage>.</citation>
</ref>
<ref id="bibr45-0884533611431068">
<label>45.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Laviano</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Aghilone</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Colagiovanni</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Metabolic and clinical effects of the supplementation of a functional mixture of amino acids in cerebral hemorrhage</article-title>. <source>Neurocrit Care</source>. <year>2011</year>;<volume>14</volume>(<issue>1</issue>):<fpage>44</fpage>-<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr46-0884533611431068">
<label>46.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dröge</surname><given-names>W</given-names></name>
</person-group>. <article-title>Aging-related changes in the thiol/disulfide redox state: implications for the use of thiol antioxidants</article-title>. <source>Exp Gerontol</source>. <year>2002</year>;<volume>37</volume>(<issue>12</issue>): <fpage>1333</fpage>-<lpage>1345</lpage>.</citation>
</ref>
<ref id="bibr47-0884533611431068">
<label>47.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bradshaw</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Brickey</surname><given-names>WW</given-names></name>
<name name-style="western"><surname>Walker</surname><given-names>KW</given-names></name>
</person-group>. <article-title>N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families [review]</article-title>. <source>Trends Biochem Sci</source>. <year>1998</year>;<volume>23</volume>(<issue>7</issue>):<fpage>263</fpage>-<lpage>267</lpage>.</citation>
</ref>
<ref id="bibr48-0884533611431068">
<label>48.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Ruderman</surname><given-names>NB</given-names></name>
</person-group>. <article-title>Muscle amino acid metabolism and gluconeogenesis [review]</article-title>. <source>Annu Rev Med</source>. <year>1975</year> <volume>26</volume>:<fpage>245</fpage>-<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr49-0884533611431068">
<label>49.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kishimoto</surname><given-names>T</given-names></name>
</person-group>. <article-title>The biology of interleukin-6 [review]</article-title>. <source>Blood</source>. <year>1989</year>;<volume>74</volume>(<issue>1</issue>): <fpage>1</fpage>-<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr50-0884533611431068">
<label>50.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Alpers</surname><given-names>DH</given-names></name>
<name name-style="western"><surname>Clouse</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Stenson</surname><given-names>WF</given-names></name>
</person-group>. <source>Manual of Nutritional Therapeutics</source>. <edition>2nd ed.</edition> <publisher-loc>Boston</publisher-loc>: <publisher-name>Little, Brown</publisher-name>; <year>1988</year>.</citation>
</ref>
<ref id="bibr51-0884533611431068">
<label>51.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hersio</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Vapalahti</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kari</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Impaired utilization of exogenous amino acids after surgery for subarachnoid haemorrhage</article-title>. <source>Acta Neurochir (Wien)</source>. <year>1990</year>;<volume>106</volume>(<issue>1-2</issue>):<fpage>13</fpage>-<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr52-0884533611431068">
<label>52.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Visser</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kritchevsky</surname><given-names>SB</given-names></name>
<name name-style="western"><surname>Newman</surname><given-names>AB</given-names></name>
<etal/>
</person-group>. <article-title>Lower serum albumin concentration and change in muscle mass: the Health, Aging and Body Composition Study</article-title>. <source>Am J Clin Nutr</source>. <year>2005</year>;<volume>82</volume>(<issue>3</issue>):<fpage>531</fpage>-<lpage>537</lpage>.</citation>
</ref>
<ref id="bibr53-0884533611431068">
<label>53.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Scocchi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Iadarola</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Protein supplementation may enhance the spontaneous recovery of neurological alterations in patients with ischaemic stroke</article-title>. <source>Clin Rehabil</source>. <year>2008</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1042</fpage>-<lpage>1050</lpage>.</citation>
</ref>
<ref id="bibr54-0884533611431068">
<label>54.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Scocchi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Boschi</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Effect of calorie-protein supplementation on the cognitive recovery of patients with subacute stroke</article-title>. <source>Nutr Neurosci</source>. <year>2008</year>;<volume>11</volume>(<issue>5</issue>):<fpage>235</fpage>-<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr55-0884533611431068">
<label>55.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Scocchi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Iadarola</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Spontaneous neurocognitive retrieval of patients with sub-acute ischemic stroke is associated with dietary protein intake</article-title>. <source>Nutr Neurosci</source>. <year>2010</year>;<volume>13</volume>(<issue>3</issue>):<fpage>129</fpage>-<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr56-0884533611431068">
<label>56.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Iadarola</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Contardi</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Branched-chain amino acids enhance the cognitive recovery of patients with severe traumatic brain injury</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2005</year>;<volume>86</volume>(<issue>9</issue>):<fpage>1729</fpage>-<lpage>1735</lpage>.</citation>
</ref>
<ref id="bibr57-0884533611431068">
<label>57.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Boselli</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Boschi</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Branched-chain amino acids may improve recovery from a vegetative or minimally conscious state in patients with traumatic brain injury: a pilot study</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2008</year>;<volume>89</volume>(<issue>9</issue>):<fpage>1642</fpage>-<lpage>1647</lpage>.</citation>
</ref>
<ref id="bibr58-0884533611431068">
<label>58.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Belayev</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Marcheselli</surname><given-names>VL</given-names></name>
<name name-style="western"><surname>Khoutorova</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection</article-title>. <source>Stroke</source>. <year>2005</year>;<volume>36</volume>(<issue>1</issue>):<fpage>118</fpage>-<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr59-0884533611431068">
<label>59.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mendez</surname><given-names>CM</given-names></name>
<name name-style="western"><surname>McClain</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Marsano</surname><given-names>LS</given-names></name>
</person-group>. <article-title>Albumin therapy in clinical practice [review]</article-title>. <source>Nutr Clin Pract</source>. <year>2005</year>;<volume>20</volume>(<issue>3</issue>):<fpage>314</fpage>-<lpage>320</lpage>.</citation>
</ref>
<ref id="bibr60-0884533611431068">
<label>60.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aquilani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Baiardi</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Scocchi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Normalization of zinc intake enhances neurological retrieval of patients suffering from ischemic strokes</article-title>. <source>Nutr Neurosci</source>. <year>2009</year>;<volume>12</volume>(<issue>5</issue>):<fpage>219</fpage>-<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr61-0884533611431068">
<label>61.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Penninx</surname><given-names>BW</given-names></name>
<name name-style="western"><surname>Leveille</surname><given-names>SG</given-names></name>
<etal/>
</person-group>. <article-title>Characteristics of nondisabled older persons who perform poorly in objective tests of lower extremity function</article-title>. <source>J Am Geriatr Soc</source>. <year>2000</year>;<volume>48</volume>(<issue>9</issue>):<fpage>1102</fpage>-<lpage>1110</lpage>.</citation>
</ref>
<ref id="bibr62-0884533611431068">
<label>62.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wu</surname><given-names>AW</given-names></name>
<name name-style="western"><surname>Yasui</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Alzola</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Predicting functional status outcomes in hospitalized patients aged 80 years and older</article-title>. <source>J Am Geriatr Soc</source>. <year>2000</year>;<volume>48</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S6</fpage>-<lpage>S15</lpage>.</citation>
</ref>
<ref id="bibr63-0884533611431068">
<label>63.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Zuliani</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Romagnoni</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Volpato</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Nutritional parameters, body composition, and progression of disability in older disabled residents living in nursing homes</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2001</year>;<volume>56</volume>(<issue>4</issue>):<fpage>M212</fpage>-<lpage>M216</lpage>.</citation>
</ref>
<ref id="bibr64-0884533611431068">
<label>64.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Selim</surname><given-names>MH</given-names></name>
<name name-style="western"><surname>Ratan</surname><given-names>RR</given-names></name>
</person-group>. <article-title>The role of iron neurotoxicity in ischemic stroke</article-title>. <source>Ageing Res Rev</source>. <year>2004</year>;<volume>3</volume>(<issue>3</issue>):<fpage>345</fpage>-<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr65-0884533611431068">
<label>65.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>de Maat</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Trion</surname><given-names>A</given-names></name>
</person-group>. <article-title>C-reactive protein as a risk factor versus risk marker [review]</article-title>. <source>Curr Opin Lipidol</source>. <year>2004</year>;<volume>15</volume>(<issue>6</issue>):<fpage>651</fpage>-<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr66-0884533611431068">
<label>66.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Arenillas</surname><given-names>JF</given-names></name>
<name name-style="western"><surname>Alvarez-Sabín</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Molina</surname><given-names>CA</given-names></name>
<etal/>
</person-group>. <article-title>C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease</article-title>. <source>Stroke</source>. <year>2003</year>;<volume>34</volume>(<issue>10</issue>):<fpage>2463</fpage>-<lpage>2468</lpage>.</citation>
</ref>
<ref id="bibr67-0884533611431068">
<label>67.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Lombardo</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Biasucci</surname><given-names>LM</given-names></name>
<name name-style="western"><surname>Lanza</surname><given-names>GA</given-names></name>
<etal/>
</person-group>. <article-title>Inflammation as a possible link between coronary and carotid plaque instability</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>25</issue>):<fpage>3158</fpage>-<lpage>3163</lpage>.</citation>
</ref>
<ref id="bibr68-0884533611431068">
<label>68.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Verma</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>CH</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>SH</given-names></name>
<etal/>
</person-group>. <article-title>A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>8</issue>):<fpage>913</fpage>-<lpage>919</lpage>.</citation>
</ref>
<ref id="bibr69-0884533611431068">
<label>69.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Liong</surname><given-names>MT</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>NP</given-names></name>
</person-group>. <article-title>Effects of a <italic>Lactobacillus casei</italic> synbiotic on serum lipoprotein, intestinal microflora, and organic acids in rats</article-title>. <source>J Dairy Sci</source>. <year>2006</year>;<volume>89</volume>(<issue>5</issue>):<fpage>1390</fpage>-<lpage>1399</lpage>.</citation>
</ref>
<ref id="bibr70-0884533611431068">
<label>70.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Olano-Martin</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Mountzouris</surname><given-names>KC</given-names></name>
<name name-style="western"><surname>Gibson</surname><given-names>GR</given-names></name>
<name name-style="western"><surname>Rastall</surname><given-names>RA</given-names></name>
</person-group>. <article-title>In vitro fermentability of dextran, oligodextran and maltodextrin by human gut bacteria</article-title>. <source>Br J Nutr</source>. <year>2000</year>;<volume>83</volume>(<issue>3</issue>):<fpage>247</fpage>-<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr71-0884533611431068">
<label>71.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Wichienchot</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Prasertsan</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Hongpattarakere</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Gibson</surname><given-names>GR</given-names></name>
<name name-style="western"><surname>Rastall</surname><given-names>RA</given-names></name>
</person-group>. <article-title>In vitro fermentation of mixed linkage glucooligosaccharides produced by <italic>Gluconobacter oxydans</italic> NCIMB 4943 by the human colonic microflora</article-title>. <source>Curr Issues Intest Microbiol</source>. <year>2006</year>;<volume>7</volume>(<issue>1</issue>):<fpage>7</fpage>-<lpage>12</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>